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Encapsulating drugs in polymeric nanoparticles (NPs) is becoming increasingly 
popular for targeted and sustained drug delivery. NP drug delivery systems can 
increase the lifetime of therapeutics in vivo, they can improve safety by allowing a 
lower dose to be administered, and they are able to pass the blood brain barrier. 
Chapter 1 will discuss the anatomy of the brain, how it can be affected by multiple 
sclerosis (MS) and why NP drug delivery has an important part to play in treating this 
disease. 
Due to the nanoscale size of these drug delivery systems, it is challenging to image 
their uptake, distribution and fate in a biological environment. Raman scattering is a 
vibrational technique which can probe the chemical bonds in a sample, however, it is 
a very weak effect. Stimulated Raman scattering (SRS) is a dual laser technique 
which increases the observed Raman signal and has been used to image biological 
samples at video-rate. Intracellular contrast can be increased further by introducing 
spectroscopically bioorthogonal chemical labels to the NPs, which appear in the so 
called cell-silent region of the Raman spectrum. Previous work to image NPs with 
fluorescence and Raman microscopies will be discussed in Chapter 1. 
In this thesis, Raman spectroscopy was used to image bioorthogonally labelled 
polymeric NPs in in vitro cellular and ex vivo tissue models of the brain. The polymer 
poly(lactic acid-co-glycolic acid) (PLGA) was chosen as a biocompatible and 
biodegradable polymer widely used in drug delivery. Chapter 2 describes the 
synthesis of PLGA with both carbon-deuterium and alkyne modifications which both 
produce Raman peaks in the cell-silent region. The optimisation of NP synthesis from 
these labelled polymers by the emulsification-evaporation method is discussed in 
Chapter 3.  
In Chapter 4, the NPs synthesised from both the deuterium and alkyne analogues of 
PLGA were imaged with SRS in biological models of the brain. Tuning to the 
bioorthogonal peaks allowed imaging of the NPs without cellular background. Both 
NP analogues were imaged in primary rat microglia, the macrophages of the brain, 
and additionally the alkyne labelled NPs were imaged in ex vivo cortical mouse brain 
slices. Immunohistochemical analysis of these brain slices confirmed that the NPs 




In order to study the effects and distribution of these particles in the body, it is 
important to be able to visualise them. However, due to their small size (~1000 times 
smaller than a cell), imaging these particles can prove challenging. In this project, new 
particles have been developed that can be imaged by Raman spectroscopy, a 
technique which can fingerprint specific bonds inside molecules. It has been shown 
that these particles can be selectively imaged in isolated rat brain cells, and also in 
cultured slices of mouse brain. These promising results pave the way for future 















Delivering drugs to their target is of upmost importance for their success in treating 
diseases, and in reducing harmful side effects. One drug delivery strategy is to load 
drugs into biocompatible and biodegradable particles. This strategy is especially 
important for delivering drugs to the brain to treat diseases like MS. The brain is 
encased in a protective layer, which prevents many drug molecules from entering, but 
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Chapter 1 Introduction 
1.1 Drug Delivery to the Brain 
As the average age of our society increases, the prevalence of neurodegenerative 
diseases of the brain are also increasing.1 There is extensive ongoing research into 
the development of drugs to treat these diseases, but the biology and anatomy of the 
brain can pose challenges for delivering these drugs to their target site.   
1.1.1 Anatomy of the brain 
The cells in the brain can be divided into neural cells which send and receive electrical 
messages, and non-neuronal glial cells which act to support and nourish the neurones. 
Glial cells include microglia which are the immune cells of the brain and act as 
macrophages to engulf foreign substances,2 astrocytes which give support to the 
neurones,3 and oligodendroglia which are involved in myelin production.4 Myelin 
production is essential for fast electrical conductance in axons and will be discussed 
further in Section 1.1.2. 
The blood vessels of the brain form part of the blood brain barrier (BBB) (Figure 1.1). 
While the skull acts to protect the brain against physical damage, the role of the BBB 
is to protect the brain from harmful chemicals and pathogens, and is a selectively 
permeable layer. 
Blood vessels are lined with endothelial cells, and in areas other than the brain, there 
are pores between these cells that allow the diffusion of substances in and out of the 
blood. In the brain, these endothelial cells form tight junctions between each other 
which will only allow the selective diffusion of some molecules and gases. The BBB 
is supported further by astrocyte end feet and pericytes, which wrap around the blood 
vessel. Molecules that can freely permeate the BBB must be highly lipophilic and less 
than 500 Da.5 Other essential molecules such as glucose are transported across the 
BBB by carrier-mediated transport. Unfortunately, many drug molecules do not fit the 







Figure 1.1 Anatomy of the BBB. Normal blood vessels have pores that allow diffusion of 
substances, but blood vessels in the brain have tight junctions that only allow selective 
transport. The BBB is supported by astrocyte end feet. Image created with Biorender.com.  
1.1.2 Multiple sclerosis and remyelination 
MS is a degenerative disease of the central nervous system (CNS) that is 
pathologically characterised with areas of focal demyelination in the brain.6 Myelin is 
a fatty tissue composed of proteins and lipids, and forms a protective sheath around 
axons in the CNS.7 Both healthy and demyelinated neurones are shown in Figure 1.2. 
Normally, oligodendrocytes will produce myelin sheaths that wrap around axons. This 
allows fast electrical conductance of signals down the axons via saltatory conduction 
between the gaps in the myelin sheath, known as nodes of Ranvier. In MS, the myelin 
sheath is damaged, degrades and, as efficient salutatory conduction can no longer 
occur, causes the symptoms and disabilities associated with MS.8 As 
oligodendrocytes also provide metabolic support via the myelin sheath to the 
underlying axon,9,10 loss of the myelin sheath can lead to axonal degradation and 
permanent disability. 
Remyelination, a process where the myelin sheath is regenerated, can take place but 
is not efficient enough over time to regenerate all damaged myelin sheaths and halt 
the effects of MS. After demyelination, oligodendrocyte precursor cells (OPCs) are 
activated and will migrate to the site of injury. Once there, the OPCs will mature into 




remyelinated axons have a smaller width and length than the original sheath, but can 
still lead to sufficient functional recovery of the axon.      
 
Figure 1.2 Demyelination causes neurodegeneration. In a healthy axon, oligodendrocytes 
produce a myelin sheath and electrical signals can jump between the nodes of Ranvier. After 
demyelination, neurodegeneration can occur (unless remyelination happens) leading to the 
symptoms of MS. Image created with Biorender.com. 
MS is widely accepted to be an autoimmune disease whereby an incorrect immune 
response is triggered, causing the body’s own immune system to degrade the myelin 
sheath. T cells are able to cross the BBB, stimulate local inflammation and lead to 
degradation of the myelin.11 Immunosuppressant therapies can be given to reduce 
this inflammatory response and avoid new MS lesions in patients.12 However, once 
the lesion has formed, can we promote remyelination and avoid subsequent 
neurodegeneration? 
Currently, clinical trials are being carried out on therapies that promote remyelination. 
For example, clemastine fumarate (Mw = 460 Da, Appendix 2), which is currently 
licenced as an antihistamine, has recently been shown to enhance myelin repair in a 
preclinical model and improve nerve conduction a small amount (suggestive of 
remyelination) in humans.13 Another potential therapy is Anti-LINGO-1 antibodies 
which act to block a protein called LINGO-1 which is known to inhibit myelin 
production.14 However, because anti-LINGO-1 is an antibody (Mw = 83 kDa) which is 
large and hydrophilic, it has low penetration across the BBB and high doses have to 
be given. Alternative strategies are therefore needed to facilitate the delivery of drugs 
to the brain.        
1.1.3 Strategies for delivering drugs to the brain  
Some lipophilic small molecule drugs can naturally penetrate the BBB, but for other 





In certain diseases, such as glioblastoma, the BBB can become leaky, and this has 
been taken advantage of to deliver drugs to the brain. In 2017, a clinical trial in humans 
with glioblastoma found that olaparib (Mw = 434.5 Da, Appendix 2), a drug licenced 
for treatment of ovarian cancers, was able to cross the BBB and was detected in the 
brain tumors.15 The BBB can also be selectively opened for a short amount of time by 
the injection of microbubbles into the blood stream, followed by application of 
ultrasound. This technique has been used to deliver drugs to the brains of mice,16 and 
in 2018, a phase I clinical trial successfully used this technique to open the BBB of 
Alzheimer’s patients.17     
The use of nanoscale drug delivery systems has also been demonstrated as an 
attractive way of delivering drugs to the brain.18 This was first achieved in 1995 by 
Kreuter et al. who successfully delivered the peptidic therapeutic dalargin (Mw = 
726 Da, Appendix 2) to the CNS of mice when encapsulated in 
poly(butylcyanoacrylate) (Appendix 3) NPs.19 The NPs were phagocytosed by 
endothelial cells in the blood brain vessels and could then release the drug inside the 
brain.  
In 2015, Rittchen et al. delivered leukaemia inhibitory factor (LIF) encapsulated inside 
PLGA NPs to the CNS of mice to promote remyelination in a MS disease model.20 LIF 
was shown to promote the maturation of OPCs to myelinating oligodendrocytes in 
vitro, and remyelination in vivo was increased when mice were administered with LIF 
loaded NPs. However, although directly injected into the brain, the location of the NPs 
over time was not detectable in ex vivo brain tissue, highlighting the need for a robust 
imaging platform capable of visualising NPs in a biological environment.     
 
1.2 Raman Spectroscopy for Biomedical Imaging 
Raman spectroscopy is a vibrational analytical technique, which measures the 
inelastic scattering of light upon interaction with a molecule. This scattering produces 
a molecular fingerprint of a sample of interest. Raman spectroscopy was first 
observed by C.V. Raman in 1928 who noticed modified scattering of light when a 
beam of sunlight was used to irradiate a variety of samples.21 Raman scattering is a 
very weak effect, as most of the light absorbed by a molecule is scattered at the same 




million molecules will scatter light at either a lower or higher energy than the incident 
light, known as Stokes or anti-Stokes scattering respectively (Figure 1.3).22 
 
Figure 1.3 The energy of Raman scattering. A) The bonds in a molecule (for example C-H 
bonds) will be excited up on irradiation with incident light (ν0). Most of the light is scattered at 
the same frequency, but a small amount is Raman scattered at a higher or lower frequency. 
B) Jablonski energy level diagrams of Rayleigh (ν=ν0), Stokes (ν<ν0) and anti-Stokes (ν>ν0) 
scattering. 
1.2.1 Spontaneous Raman scattering 
Spontaneous Raman spectroscopy is the simplest form of Raman spectroscopy 
where a single laser is used to excite all of the bonds in a molecule to produce a 
fingerprint. The Stokes scattering is usually detected since more molecules populate 
the ground state at ambient temperature, which leads to a stronger signal. 
In contrast to infrared spectroscopy, water gives low Raman scattering meaning that 
it is an ideal technique for analysing biological samples.23 Figure 1.4 shows the 
spontaneous Raman spectrum of microglia. Plotting Raman intensity resulting from 
excitation with a 532 nm laser against Raman shift gives rise to the characteristic 
cellular spectrum. There are large peaks for CH3 (2939 cm-1) and CH2 (2856 cm-1) 
which are indicative of cellular proteins and lipids respectively, and smaller peaks in 
the fingerprint region due to carbonyl bonds in the protein backbone (1663 cm-1) and 
the aromatic ring in the amino acid phenylalanine (1004 cm-1). There is an absence 





Figure 1.4 The spontaneous Raman spectrum of primary rat microglia. Microglia were 
analysed by spontaneous Raman spectroscopy, λex = 532 nm, showing characteristic cellular 
peaks and the cell silent region.  
The laser detection system for spontaneous Raman spectroscopy can be appended 
to a confocal microscope, and this system can be used to image cells and tissues by 
taking a Raman spectrum at each pixel.24 This allows a distribution image of chemical 
species corresponding to cellular organelles to be built up, allowing label-free imaging.  
1.2.2 Analysis of Raman imaging data 
Large amounts of data can be generated when spontaneous Raman spectroscopy is 
interfaced with the spatial power of a scanning imaging technique. Hyperspectral 
Raman imaging, or Raman mapping, involves acquisition of a Raman spectrum at 
each pixel; it has been used to image plaques in the brains of Alzheimer’s patients,25 
and for the diagnosis of cancer.26–28 The raw data acquired from the Raman 
spectrometer may be processed with chemometric methods to distinguish small 
changes in spectroscopic peaks in order to de-convolute chemical substances in each 
pixel. Two common chemometric methods are principal component analysis (PCA) 
and vertex component analysis (VCA).29,30 Both methods allow the deconvolution of 
each pixel’s spectrum into main spectral components which can then be used to build 
up a quantitative representation of each cell.  
1.2.3 Surface enhanced Raman scattering 
Since Raman scattering is a very rare event, acquisition of spectra from biological 




instrumental methods have been designed to amplify the Raman signal. Surface 
enhanced Raman spectroscopy (SERS) is a technique where a Raman reporter is 
appended to a roughened metal surface,31 usually a gold or silver NP, to achieve an 
enhancement of signal in the order of 104 to 108 compared to spontaneous Raman.32 
SERS has been used for many biological applications such as lipid bilayer 
characterisation,32 sensing intracellular redox potentials,33 and pathogen diagnosis.34 
1.2.4 Coherent Raman scattering 
Coherent Raman scattering describes non-linear techniques where two incident 
lasers are used to excite and image a particular vibration of interest and increase 
Raman signal. Coherent anti-Stokes Raman scattering (CARS) and SRS are two 
coherent Raman techniques which have been used in many biological 
applications.35,36 CARS uses two lasers, the pump laser (ωp) and Stokes laser (ωs), 
which interact with the sample in a four-wave mixing process to generate signal at the 
anti-Stokes frequency, Ω (ωas = 2 ωp- ωs) (Figure 1.5 A). CARS can achieve video-
rate imaging of biological samples, and is also suited to depth analysis of cells and 
tissues.37 When Ω matches a molecular vibration of interest, contrast is derived from 
the chemical bonds in the sample,38 but the process can also occur in non-resonant 
conditions leading to issues with high background noise. 
The development of SRS for biological imaging overcame this issue as it does not 
suffer from non-resonant background.39,40 Like CARS, SRS also employs the 
excitation of a sample with a pump and Stokes laser, and SRS occurs when Ω 
matches a molecular vibration (Figure 1.5 A). The stimulated emission is detected as 
a loss of intensity in the pump beam (stimulated Raman loss, SRL) or a gain in 
intensity of the Stokes beam (stimulated Raman gain, SRG).41 SRL and SRG do not 
occur when Ω does not match a molecular vibration, and so there can be no non-
resonant background. There is also a quantitative linear relationship between 
concentration of a molecule of interest and SRS intensity.42 Compared to 
spontaneous Raman spectroscopy, SRS gives a signal enhancement in the order of 
108,43 and also a 1000 fold improvement in the speed of image acquisition, making it 





Figure 1.5 Coherent Raman scattering. A) Energy level diagrams showing the process of SRS 
and CARS. In SRS, a sample is excited with a pump and Stokes laser to create an image 
when Ω matches a molecular vibration. CARS is a four wave mixing process where Ω is tuned 
to the anti-Stokes frequency. B) SRS images of primary rat microglia when Ω = 2939 cm−1 
(CH3, proteins, grey), 2856 cm−1 (CH2, lipids, cyan), 1663 cm−1 (amide I, magenta) and 2078 
cm-1 (off-resonance, grey). Scale bars = 5 µm. 
Figure 1.5 B shows representative SRS images acquired of a microglia. Tuning Ω to 
the large CH3 peak at 2939 cm−1 produces a label-free image indicative of the cellular 
protein content. Similarly, tuning Ω to 2856 cm−1 builds up a strong signal from the 
CH2 content which is present in membranous structures in the cell and absent from 
the nucleus. The amide I peak at 1663 cm−1 also shows the cellular proteins, but with 
a weaker signal than the CH3 peak. Importantly, tuning to 2078 cm-1, which is in the 
cell-silent region, produces very little signal. 
1.2.5 Bioorthogonal Raman labels 
Bioorthogonal chemical reactions are defined as ones that can react with, or label, 
biomolecules in their natural environment without causing any toxicity or perturbation 
to the living system.45 As such, the term bioorthogonal has been adopted for Raman 
labels that consist of bonds not found in the native biological environment and lie in 
the cell-silent region, but that will also not cause toxicity. 
As shown in Figure 1.4, there is a region absent of any cellular Raman peaks from 
~1800–2800 cm-1. This region can be exploited with small, bioorthogonal chemical 
labels so that molecules of interest can be imaged free of cellular background. 




deuterium bonds (C-D). An advantage of Raman imaging over fluorescence is that 
these chemical labels are small compared to fluorophores which should limit 
perturbation of biological function.46 Molecules that already contain one of these 
bonds in their natural structure can be imaged label-free, for example the tyrosine 
kinase inhibitor neratinib 1 which contains an intrinsic nitrile (Figure 1.6 A).47 
Molecules can also be chemically modified to contain one of these bonds.  
The majority of previous work has focused on alkyne bioorthogonal labelling because 
of its superior Raman signal.46 5’-Ethynyl-2’-deoxyuridine (EdU) 2 is an analogue of 
the nucleobase thymine and is often used to image DNA in live cells, either by 
conjugation of a fluorophore to the alkyne through a copper-catalysed azide-alkyne 
click (CuAAC) reaction, or more recently by imaging the alkyne with SRS microscopy 
(Figure 1.6 B).42 Hu et al. have produced an alkyne tagged analogue of glucose 3 and 
showed that it is taken up into various cell and tissue types, with Figure 1.6 C showing 
uptake into mouse neurones.  
 
Figure 1.6 Imaging with bioorthogonal Raman labels. A) The tyrosine kinase inhibitor neratinib 
1 contains an intrinsic nitrile and was imaged by Raman spectroscopy in SKBR-3 cells, C-H in 
blue (cellular proteins) and C≡N in red (neratinib). Reproduced with permission,47 copyright 
John Wiley and Sons. B) EdU 2 allows visualisation of cell division in HeLa cells, C=O in blue 
(cellular proteins) and C≡C in red (DNA). Reproduced with permission,42 copyright Springer 
Nature. C) Primary mouse neurones can be imaged when incubated with alkyne labelled 




1.2.6 Medical applications of Raman spectroscopy 
Raman spectroscopy is highly compatible with biological samples, and is also non-
destructive, so has become an attractive analytical technique for many biomedical 
applications.49 Spontaneous Raman has been used for label free diagnostics on 
tissue samples, as healthy and diseased cells will often display different spectroscopic 
fingerprints,50 and coherent Raman imaging methods can be used in parallel with 
traditional histological staining.51 The majority of diagnostic studies have been carried 
out on cancers. Metastatic tumours are often associated with expression of surface 
sialic acid. Shashni et al. used a SERS probe to target this sialic acid to better 
diagnose metastatic cancers.52 Raman spectroscopy can also be combined with other 
analytical techniques such as fluorescence or mass spectrometry to give a more 
detailed picture of the properties of the sample.53 
Raman is also compatible with fibre-optics, and Raman probes have been attached 
to the end of probes used in endoscopies to provide in vivo, live spectroscopic 
information. Near infrared excitation lasers (e.g. 785 nm) are usually used for in vivo 
applications for enhanced tissue penetration, and to limit tissue auto-fluorescence 
which can easily mask the Raman signal.54 Again, cancer diagnosis has been 
prominent in the field of Raman fibre-optics. In 2017, Lin et al. reported Raman 
diagnosis of nasopharyngeal carcinoma, a type of throat cancer, during endoscopy.55 
This involved study of 57 healthy and 38 cancer subjects, and the diagnostic accuracy 
was 93%. As well as during endoscopy, Raman probes have also been used to 
diagnose skin cancer.56,57 These studies show the potential of Raman spectroscopic 
analysis to give real-time clinical diagnostics without the invasiveness of a biopsy. 
 
1.3 Nanoparticle Imaging 
As discussed in Section 1.1.3, NP drug delivery has the potential to increase in vivo 
efficacy and deliver drugs to the brain. In order to study the mode of action of the NPs 
and to address safety concerns, it is critical to be able to image the NPs in a biological 
environment. Previously, polymeric and lipid-based NPs have been imaged using 
fluorescence, confocal Raman and coherent Raman microscopies.58 When imaging 
a fluorescent payload, this can leak out of the NP over time and can also suffer from 
photobleaching. In contrast, NPs can be imaged directly with Raman spectroscopy 





Figure 1.7 Strategies for intracellular imaging of NPs. NPs can be loaded with a fluorescent 
dye to allow imaging with fluorescence microscopy, but this can suffer from issues such as 
leakage of the dye or photobleaching. NPs can be imaged directly, with or without 
bioorthogonal labels, by Raman spectroscopy.  
1.3.1 Fluorescence  
Fluorescent NPs are common in biomedical imaging applications as they often have 
increased brightness, higher photostability and lower toxicity than traditional 
fluorophores.59 A variety of materials can be formulated into fluorescent NPs including 
silica,60 organic polymers and quantum dots.61 Many of these NPs are commercially 
available with surface groups to allow further chemical functionalisation.  
Andreiuk et al. synthesised a palette of fluorescent PLGA NPs and used them to label 
cells and track them over time in both co-cultures and zebrafish embryos.62 They 
encapsulated red, blue and green cyanine dyes inside PLGA NPs and incubated 
these NPs with different cell lines to yield red, green and blue cells. Culturing cells 
with combinations of these NPs also produced yellow, magenta and cyan cells (Figure 
1.8 A). These cells were then co-cultured and each cell line could be identified by its 
unique colour (Figure 1.8 B). This labelling strategy was also applied to cancer cells 





Figure 1.8 Labelling cells with fluorescent NPs. A) PLGA NPs were loaded with green (DiI), 
red (DiD) and blue (DiO) cyanine dyes and incubated with different cell lines. Incubating with 
two different NPs produced yellow, cyan and magenta coloured cells. B) Six different cell lines 
were cultured with NPs to produce six different coloured cells which were then co-cultured. 
Scale bar = 100 µm. Reproduced with permission,62 copyright John Wiley and Sons.  
Kalluru et al. used PLGA NPs to deliver antibiotics to a cellular model of Myobacterium 
tuberculosis, and also loaded the NPs with the fluorescent dye coumarin-6 in order to 
study their cellular location and fate.63 They observed that the NP signal co-localised 
with lysosomes, and that the fluorescent signal dropped off steadily over 13 days. 
PLGA degrades by hydrolysis in an aqueous environment,64 so the authors 
hypothesised that the loss of fluorescent signal was due to diffusion of the dye out of 
the NP over time, making it a good model of intracellular drug release. 
In addition to loading polymer NPs with a fluorescent dye, NPs can also be fabricated 
from fluorescent polymers. Conjugated polymer NPs are an attractive class of 
fluorescent NPs, and have been used for biomedical imaging and theranostic 
applications.65,66 Poly(phenylene ethynylene) (PPE) (Appendix 3) is a conjugated 
polymer used for both imaging and drug delivery. Chen et al. loaded PPE NPs with 
the anticancer drug doxorubicin and showed that they could image the NPs with 
fluorescence microscopy, and that cell death was caused upon release of the drug.67 
Additionally, conjugated polymers capable of producing reactive oxygen species have 
been loaded into a NP matrix and targeted to cancer cells.68 These NPs can be used 




1.3.2 Confocal Raman 
As discussed in Section 1.2.1, a Raman laser can be appended to a confocal 
microscope to give a set-up capable of using Raman scattering to image cells and 
tissues by scanning across the sample and taking a Raman spectrum at each pixel. 
Confocal Raman has been used to image polymeric NPs both label-free, and utilising 
small bioorthogonal tags. 
In 2017, Li et al. used water soluble analogues of the conjugated polymer PPE, which 
contains an intrinsic alkyne, to fabricate NPs which could then be imaged in HeLa 
cells with Raman microscopy by tuning to the alkyne peak.69 The chemical structure 
of PPE makes it a good candidate for bioorthogonal Raman imaging because the 
alkyne produces a bioorthogonal peak in the cell silent region, and the conjugation of 
this alkyne bond between aromatic rings greatly enhances its Raman signal.  
In a similar way to loading with fluorescent dyes, NPs can be loaded with a 
bioorthogonally Raman active payload and imaged. Two studies have used this 
approach to investigate the uptake of NPs to cells over time. The kinetics of NP uptake 
can be affected by particle size, composition and zeta potential.70 Chernenko et al. 
loaded polymer NPs with a deuterated analogue of the drug ceramide (Mw = 408.7 Da, 
Appendix 2) which allowed the NPs to be visualised in SKOV-3 cells after VCA (Figure 
1.9 A).71 SKOV-3 cells are a model of ovarian cancer and are known to express 
epidermal growth factor receptor (EGFR). The NPs could be targeted to EGFR and 
these NPs were shown to be preferentially taken up into the cells over non-targeted 
NPs. 
Matthäus et al. loaded PLGA-NPs with β-carotene which allowed the NPs to be 
imaged with Raman spectroscopy in murine NIH-3T3 cells.72 β-Carotene (Mw = 
537 Da, Appendix 2) has an extended conjugated structure, and this means that 
resonance Raman spectroscopy can be employed where the energy of the incident 
laser matches the electronic transition of the sample. This can lead to an 
enhancement of Raman signal of 103 to 104 over spontaneous Raman 
spectroscopy,73,74 which in turn allowed the uptake of the NPs to be imaged over time 
(Figure 1.9 B). 
The uptake of deuterated liposomes has also been studied by Raman spectroscopy.75 
One treatment group of liposomes were conjugated to TAT peptide, an amino acid 




conjugated liposomes were visible in MCF-7 cells after 6 hours, while the un-
conjugated liposomes were not detected until 12 hours. 
 
Figure 1.9 Imaging NPs with confocal Raman. A) The uptake of EGFR targeted NPs to SKOV-
3 cells over time shows intracellular NPs after two hours. Images are created from VCA 
analysis by overlaying the cell body and nucleus (blue), membranous organelles (green), early 
endocytic vesicles (yellow), and nanoparticles (red). White arrows show regions of 
nanoparticle aggregation. Reproduced with permission,71 copyright Springer Nature. B) The 
uptake of β-carotene loaded PLGA nanoparticles into murine NIH-3T3 cells by VCA analysis 
showing the cell body (cyan) and nanoparticles (red). Scale bar = 10 µm. Reproduced with 
permission,72 copyright John Wiley and Sons.  
In addition to studying NP uptake, the degradation of NPs can be inferred by 
observing their signal reduction with Raman imaging. This is important for addressing 
safety concerns about the long-term fate of NPs. In 2004, van Apeldoorn et al. used 
spontaneous Raman spectroscopy to study the degradation of PLGA microspheres 
in macrophages.77 PLGA degrades via hydrolysis of its ester bonds, and this 
corresponded to a decrease in the ester peak (1768 cm-1) of the microspheres after 
being exposed to macrophages for two weeks. Figure 1.10 A shows the decrease in 
this ester peak, and that there is also an increase in cellular peaks (1658, 1440 and 
1004 cm-1) which fill the void left by the microsphere. Control experiments showed 
that microspheres not exposed to macrophages did not show any degradation over 





Figure 1.10 Raman analysis of NP degradation. A) The degradation of PLGA nanoparticles in 
macrophages over two weeks. Comparison of control PLGA (black spectrum) and PLGA that 
has been incubated with macrophages for two weeks (red spectrum). The green spectrum is 
the difference between the two. Reproduced with permission,77 copyright American Chemical 
Society. B) Images of HeLa cells and PLGA NPs from VCA analysis showing proteins in blue, 
lipids in green, and nanoparticles in red. After two hours of incubation with NPs they were 
visible by Raman. After three hours incubation with NPs then three or six hours of incubation 
with fresh media, NPs were no longer visible. Reproduced with permission,78 copyright 
American Chemical Society.  
Chernenko et al. carried out label-free imaging of PLGA NPs in HeLa cells and used 
VCA to un-mix the individual spectra of the NPs from the proteins, lipids and 
membranous structures of the cell.78 After two hours of exposure to the NPs, they 
were visible in the cells (Figure 1.10 B, left image). After three hours of exposure to 
the NPs, followed by exposure to fresh media for either three or six hours, it was found 
that the NPs were no longer visible (Figure 1.10 B, centre and right images). 




1.3.3 Coherent Raman 
As mentioned in Section 1.2.4, SRS and CARS have been popular techniques for 
biological imaging, including the imaging of NPs in cells and tissues. In 2017, Hu et 
al. synthesised styrene-based polymer dots with bioorthogonal alkyne, nitrile and 
carbon-deuterium Raman labels, and imaged them in HeLa cells with SRS.79 These 
peaks all appear in the cell-silent region and do not overlap with each other making 
them mutually orthogonal. This is a significant advantage of Raman over fluorescence, 
as the narrow Raman peaks allow enhanced multiplex imaging. Figure 1.11 shows 
the three polymer dots imaged in live HeLa cells. A further experiment saw the three 
colours of dots being incubated with three different cell lines which were then co-
cultured and could be sorted by their Raman label. 
 
Figure 1.11 Imaging bioorthogonal polymer dots in HeLa cells with SRS. Alkyne (A), nitrile (B) 
and carbon-deuterium (C) bonds were introduced into styrene based polymer dots which were 
mutually orthogonal and could be imaged in live HeLa cells with SRS. Reproduced with 
permission,79 copyright Royal Society of Chemistry.  
Both CARS and SRS have also been used to image NPs in tissue samples. A tissue 
model of topical drug delivery to the skin was treated with deuterated methyl 
methacrylate NPs, and the penetration of these NPs into the skin was visualised with 
SRS.80 Additionally, CARS has been used to assess the distribution of deuterated 
quaternary ammonium palmitoyl glycol chitosan NPs ex vivo in various organs.81–83 
These studies show the potential of coherent Raman spectroscopy to image 






The treatment of diseases of the brain, including MS, is hindered by the inability of 
many drugs to cross the BBB.84 The encapsulation of drugs into biodegradable and 
biocompatible nanoscale carriers has been shown to successfully deliver drugs 
across the BBB in a variety of disease models. However, visualisation of this delivery 
proves challenging because of the small size and poor signal-to-background contrast 
of these NPs.  
NPs have been imaged in cells and tissues with a variety of techniques including 
fluorescence and Raman microscopies. Raman scattering can provide a platform for 
label-free NP imaging, but small bioorthogonal labels have also been shown to 
improve contrast of these NPs against the cellular background. Raman spectroscopy 
therefore has the potential to allow the imaging of NPs for applications in drug delivery 
to the brain. Imaging NPs is particularly important for an enhanced understanding of 
drug delivery systems as more clinical NP applications are realised. 
 
1.5 Project Aims 
The aims of this project are to use SRS microscopy to image spectroscopically 
bioorthogonal analogues of PLGA NPs for applications in drug delivery to the brain. 
The previous work discussed in this chapter has highlighted how Raman scattering 
can be used to successfully image a variety of NPs in biological environments, with 
or without bioorthogonal labels. The aim of the current work is to conjugate 
bioorthogonal labels to PLGA, which is a highly relevant polymer for drug delivery and 
has not been imaged by SRS before. Once these polymers have been synthesised, 
they will be fabricated into NPs and surface functionalisation and targeting strategies 
will be explored. Finally, SRS microscopy will be used to image these NPs in cellular 
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Chapter 2 Synthesis of Bioorthogonal Raman 
Labelled Polymers 
2.1 Introduction 
2.1.1 Polymer synthesis 
Polymers are versatile materials that are composed of a repeating unit of monomers. 
This broad definition of polymers includes natural biopolymers, such as proteins, 
which are made of repeating units of amino acids, and synthetic materials used for 
plastics such as polyesters, which will be the focus of this thesis.  
As a global concern for the overuse and waste management of plastics grows, 
research into biodegradable polymers is becoming prominent.85 Poly(lactic acid-co-
glycolic acid) (PLGA) 8 is a biodegradable and biocompatible polyester that has been 
used extensively in medical research,64,86–88 and has a circular ‘lifecycle’ as shown in 
Figure 2.1. 
 
Figure 2.1 The lifecycle of PLGA. Lactic acid 4 and glycolic acid 5 can be polymerised via a 
polycondensation reaction to form PLGA 8, which subsequently breaks down over many 
hydrolysis steps back to lactic and glycolic acid. Alternatively, lactic and glycolic acid can be 
ring closed to form the cyclic di-esters lactide 6 and glycolide 7 respectively, which can then 
undergo ring opening polymerisation (ROP) to produce higher molecular weight PLGA. 
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Lactic acid can be produced from biomass, which is a renewable source; however, 
there are significant costs associated with its isolation and purification. The advantage 
of using this method over traditional chemical synthesis is that D,L-lactic acid 4 can be 
prepared.89 Glycolic acid 5 is an achiral α-hydroxy acid that has traditionally been 
produced chemically from fossil fuels, however, research is ongoing into renewable 
production, with glycolic acid biosynthesis in yeast reported in 2013.90 
These two monomers can be co-polymerised to produce PLGA. The physical and 
chemical properties of the resulting polymer may be tuned by variation of the ratio of 
lactic acid to glycolic acid used in the monomer feedstock. A higher proportion of lactic 
acid produces a more hydrophobic polymer that will take longer to degrade in a 
biological environment; this is an important consideration when designing a drug 
delivery vehicle.91,92  
Figure 2.1 shows two ways of producing PLGA: a direct polycondensation from lactic 
and glycolic acid, and ring opening polymerisation (ROP) from the cyclic di-esters 
lactide 6 and glycolide 7. New developments of these methods of polymerisation for 
poly lactic acid (PLA) have recently been reviewed by Hu et al.93  
Polycondensation is driven by the elimination of water as two molecules of 
lactic/glycolic acid join together in a condensation reaction. This process repeats itself 
to produce chains of increasing molecular weights. A limiting factor of this method is 
that the presence of water can cause the reverse hydrolysis reaction to take place, 
and thus limit the molecular weight of the polymer. However, steps can be taken to 
remove this water such as adding molecular sieves to the reaction, or fitting the set-
up with a Dean-Stark trap. 
ROP is an attractive process for polymer formation due to its ability to produce high 
molecular weights and low polymer dispersity (Ð),94 and is often used in the production 
of PLGA 8. Lactic/glycolic acid first have to be ring closed to their corresponding cyclic 
di-esters lactide and glycolide. Traditionally, this has been achieved by first 
dehydrating the α-hydroxy acid to form oligomers, and then adding a metal catalyst 
to cause a back-biting reaction which in turn produces the cyclic structure.95 This is 
often a low yielding reaction requiring high temperatures and pressures, and produces 
a mixture of enantiomers. Current research is focused on finding more sustainable 
one-step syntheses of lactide including shape selective zeolite catalysis,96 and a gas 
phase synthesis which has recently been reported by Heo et al.97   
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The ROP reaction proceeds via a coordination-insertion mechanism, generally 
catalysed by a metal alkoxide catalyst, with the mechanism shown in Scheme 2.1. 
 
Scheme 2.1 The coordination-insertion mechanism of ROP. PLGA 8 is synthesised through 
ROP of the cyclic di-esters lactide 6 and glycolide 7.98 Firstly, a metal pre-catalyst is mixed 
with an alcohol to form the active metal alkoxide catalyst. Through a coordination-insertion 
mechanism this catalyses ring opening of the cyclic di-esters. 
The most popular catalyst for ROP is tin(II) 2-ethylhexanoate (Sn(oct)2) due to its high 
solubility in organic solvents or melts, and ability to produce high molecular weight 
polymers. However, although the catalyst is FDA approved,99 the residual tin 
contamination is a concern, especially for biomedical applications. Research is 
ongoing into the use of alternative, less toxic metals such as aluminium,100,101 and also 
into organocatalysts.102–104  
2.2.2 Polymer characterisation 
PLGA 8 is characterised by 1H NMR spectroscopy in order to determine the ratio of 
poly(lactic acid) (PLA) to poly(glycolic acid) (PGA) in the final polymer (Section 2.3.1). 
Polymer molecular weight is determined by gel permeation chromatography (GPC). 
GPC determines the weight average molecular weight, Mw, and the number average 
molecular weight, Mn. The dispersity of the polymer (Ð) is defined as Mw/Mn and would 
be 1.0 for a polymer where all the chains are the same length. The dispersity gives a 
good indication of the control the catalyst has on the polymerisation, as side reactions 
can increase the dispersity. 
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2.2 Routes to Deuterated Monomers  
In order to be able to image PLGA 8 with bioorthogonal SRS imaging in the cell-silent 
region, the aim was to introduce carbon-deuterium bonds into the polymer. The 
Raman shift of a chemical bond is proportional to its reduced mass,105 so a 100% 
increase of mass, as is the case with a hydrogen to deuterium substitution, will 
decrease the frequency of the bond and move the Raman shift into the cell-silent 
region (1800–2800 cm-1).  
To give the highest chance of obtaining a sufficient Raman signal, as the carbon-
deuterium stretch is known to have a relatively small Raman cross-section,46 it was 
decided to introduce carbon-deuterium bonds into a PLGA monomer, so that each 
repeating unit of the polymer would contribute to the Raman signal. 
2.2.1 Alkylation route 
2.2.1.1 Synthesis of lactic acid-d3 
Lactic acid 4 contains a CH3 group, and the aim was to substitute this CH3 group to a 
CD3 to produce Raman peaks in the cell-silent region. To produce lactic acid-d3, a 
synthetic route was derived using deuterated iodomethane (CD3I) as an alkylating 
agent. Firstly, two protection steps were carried out to protect the free acid and free 
alcohol of glycolic acid (Scheme 2.2). The first step involved the reaction of 
bromoacetic acid 9 with potassium tert-butoxide 10 to obtain 2-(tert-butoxy)acetic acid 
11, which was high yielding and easily scalable.  
 
Scheme 2.2 Formation of methyl 2-(tert-butoxy)acetate 12. Reagents and conditions: i) THF, 
75°C, 1 h; ii) TMSCl, MeOH, rt, 0.5 h. 
The second step attempted to protect the free acid as a methyl ester utilising TMSCl 
and methanol, with crude NMR analysis showing that the desired product 12 had been 
formed. However, after working up the reaction, NMR analysis showed that the 
product had decomposed, specifically that the tert-butyl group had been cleaved. It 
was hypothesised that the hydrochloric acid produced as a side product in the reaction, 
combined with the heat from the rotary evaporator, gave sufficient conditions to cleave 
the tert-butyl group. It was also observed that much of the product was being lost on 
the rotary evaporator. To overcome these problems, a Steglich esterification strategy 
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(Scheme 2.3) was successfully employed using 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC), 4-dimethylaminopyridine (DMAP) and 
benzyl alcohol.106 Benzyl alcohol was chosen instead of methanol to try to increase 
the boiling point of the product, so that it would not be lost during solvent removal.  
 
Scheme 2.3 A Steglich esterification for the formation of benzyl 2-(tert-butoxy)acetate 13. 
Reagents and conditions: i) benzyl alcohol, EDC, DMAP, DCM, rt, 18 h.  
In the third step, a strong, non-nucleophilic base was used to form the enolate of 
benzyl 2-(tert-butoxy)acetate 13, which was subsequently quenched by the addition 
of deuterated iodomethane (Scheme 2.4).  
 
Scheme 2.4 Alkylation proceeded via an enolate intermediate to produce benzyl 2-(tert-
butoxy)(3,3,3-²H₃)propanoate 14. Reagents and conditions: i) Li/KHMDS, THF, -78°C, 0.5 h; 
ii) CD3I, THF, -78°C – rt, 0.5 h. 
Initially this reaction was low yielding (~20%), so a number of bases and solvents 
were screened, along with further purification of the benzyl 2-(tert-butoxy)acetate 13 
starting material. The conditions used in these reactions and their resulting yields are 
tabulated in Table 2.1. All reactions were carried out on a 0.5 g scale on the same 
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KHMDS 1.5 1.1 THF No column 22 
LiHMDS 1.5 1.1 THF No column 25 
KHMDS 1.5 1.1 THF Column 29 
KHMDS 1.5 1.1 Toluene Column 11 
LiHMDS 1.5 1.1 THF Column 28 
LiHMDS 2.5 1.1 THF Column 34 
KHMDS 2.5 2.0 THF Column 45 
LiHMDS 2.5 2.0 THF Column 38 
a CD3I was filtered through a plug of anhydrous potassium carbonate prior to use. 
Table 2.1 shows that the optimum conditions for alkylation used THF as the solvent, 
2.5 equivalents of KHMDS and 2 equivalents of iodomethane. The yields listed in 
Table 2.1 are not higher than 45% which is due, in part, to the formation of an impurity. 
Thin layer chromatography (TLC) analysis during the reaction showed that all the 
starting material was consumed, but that there was another spot in addition to the 
product. The product 14 and impurity 16 were separated by flash column 
chromatography, and NMR analysis provides evidence that the impurity is the Claisen 
condensation product from two molecules of the starting material (Scheme 2.5).  
 
Scheme 2.5 An impurity 16 is formed due to a competing Claisen condensation. 
To try and minimise the formation of this impurity 16, additional equivalents of 
iodomethane could have been added to push the equilibrium towards the desired 
product, or shorter reaction times could have been investigated. 
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The protonated analogue, benzyl 2-(tert-butoxy)propanoate 15, was also synthesised 
and both 1H and 13C NMR provide evidence for the CD3 group, with a comparison of 
the two 1H NMR spectra shown in Figure 2.2.  
 
Figure 2.2 Comparison of the 1H NMR spectra of benzyl 2-(tert-butoxy)(3,3,3-²H₃)propanoate 
14 (top) and benzyl 2-(tert-butoxy)propanoate 15 (bottom). 
Benzyl 2-(tert-butoxy)propanoate 15 shows a doublet corresponding to the methyl 
group at ~1.25 ppm, which is absent in the deuterated analogue benzyl 2-(tert-
butoxy)(3,3,3-²H₃)propanoate 14. 
Evidence for the CD3 can also be seen in the 13C NMR; the carbon of the CD3 group 
appears as a septet, whereas the protonated analogue shows a singlet (Figure 2.3).  




Figure 2.3 Comparison of the 13C NMR spectra of benzyl 2-(tert-butoxy)(3,3,3-²H₃)propanoate 
14 (top) and benzyl 2-(tert-butoxy)propanoate 15 (bottom). 
Subsequently, two deprotection steps were carried out to afford lactic acid-d3. It was 
decided to utilise orthogonal protecting groups, and remove them sequentially, as 
after cleavage of the tert-butyl group the product could be purified by flash column 
chromatography which would not be possible if both were cleaved at the same time. 
Initially, trifluoroacetic acid in DCM was used to remove the tert-butyl group (Scheme 
2.6), but this gave long reaction times and moderate yields. 
 
Scheme 2.6 Deprotection of benzyl 2-(tert-butoxy)(3,3,3-²H₃)propanoate 14 to afford benzyl 
2-hydroxy(3,3,3-²H₃)propanoate 17. Reagents and conditions: i) TIS, TFA (5% v/v), DCM, rt, 
24 h, 67%; ii) TiCl4 (1 M in DCM, 10% v/v), DCM, -78 °C, 15 min, 94%. 
Titanium tetrachloride in DCM (Scheme 2.6) gave a higher yield and significantly 
shorter reaction times. 
Finally, the benzyl protecting group was removed via a hydrogenation reaction to 
afford the final product, lactic acid-d3 18 (Scheme 2.7). The optimised five-step 
sequence gave an overall yield of 28%. 




Scheme 2.7 Benzyl deprotection of benzyl 2-hydroxy(3,3,3-²H₃)propanoate 17 to give lactic 
acid-d3 18. Reagents and conditions: i) Pd/C, H2, THF, rt, 3 h. 
2.2.1.2 Comparison with commercial lactic acid-d3 
Lactic acid-d3 is also commercially available, so a sample of the commercial material 
was used to compare the characterisation with the material made in-house. Figure 
2.4 shows that the 1H and 13C NMR spectra of the commercial material is identical to 
the material synthesised in-house, confirming that the synthetic route has been 
successful.  
 
Figure 2.4 Comparison of the 1H (A) and 13C (B) NMR spectra of commercial lactic acid-d3 
(bottom) with material synthesised in-house (top). The small impurity peak present in the 1H 
NMR of the commercial product could be due to oligomers that can form in an aqueous solution. 
Evidence for the presence of deuterium is clear from the septet in the carbon NMR, 
and the material synthesised in-house was also analysed by spontaneous Raman 
spectroscopy and 2H NMR, which both show deuterium peaks (Figure 2.5).  




Figure 2.5 Analysis of lactic acid d3 18 by spontaneous Raman spectroscopy, λex 785 nm (A) 
and 2H NMR (B). 
2.2.1.3 Ring closing reactions 
As the most common route to PLGA 8 is via ring opening polymerisation, which gives 
superior molecular weights and dispersity when compared to the direct condensation 
method,94 ring closing reactions were investigated in order to produce lactide-d6 20. 
Considering the number of steps taken to produce lactic acid-d3 18 and the high cost 
of buying it commercially, the investigative reactions were carried out on lactic acid 4, 
which is inexpensive and commercially available. 
Throughout the literature, modest yields are reported for the ring closing of lactic acid 
4 to lactide 6, as longer oligomers are formed as by-products.95 The first method 
attempted was the two-step reaction, where the lactic acid was dehydrated to form 
oligomers, followed by a back-biting reaction catalysed by tin to afford ring closed 








Scheme 2.8 Formation of lactide 6 from lactic acid 4 in one or two-step processes. Reagents 
and conditions: i) 230°C, 6 h; ii) Sn(oct)2, 230°C, 20 mbar, 2 h; iii) para-TSA, toluene, 130°C, 
4 days; iv) Yt(III) triflate, toluene, 130°C, 18 h; v) H-beta zeolite, toluene, 130°C, 3 h.   
The two-step reaction in Scheme 2.8 (i, ii) was very low yielding, with only a 2% yield 
of racemic lactide. The yield of the crude lactide was higher due to racemisation 
producing meso lactide, but after purification by recrystallization or column 
chromatography much of the material was lost. It was also clear during the reaction 
that there were a lot of discoloured oligomers left in the flask that had not converted 
to lactide, with the heat and reduced pressure also facilitating reaction of the 
oligomers to form longer chains.  
To try and improve the yield, and remove the need for the initial oligomerisation step, 
several one-pot reactions were investigated utilising various catalysts to favour the 
formation of lactide over PLA oligomers 19 (Scheme 2.8, iii, iv or v). All of these 
reactions were setup with a Dean-Stark trap to remove water from the system. The 
yields of these reactions are listed in Table 2.2. 
Table 2.2 One-pot ring closing reactions with various catalysts 
Reagentsa Conditions % yield lactide 
p-TSA in 400 mL toluene Reflux, 4 days Only oligomers 
Yt(III) triflate in 400 mL 
tolueneb 
Reflux, 18 h 3 
H-beta zeolitec in 10 mL 
toluene 
Reflux, 3 h 34 
aReactions were carried out on 1.2 g lactic acid (85%, aq)  
bThe starting material for this reaction was ammonium lactate produced by reacting lactic acid 
with ammonium hydroxide 
cZeolite was calcined at 550°C overnight prior to use, 0.5 wt% used 
 
Synthesis of Bioorthogonal Raman Labelled Polymers 
39 
 
The p-TSA and Yt(III) triflate reactions were carried out at very dilute concentrations 
(0.028 M) in the hope that only two molecules of lactic acid would meet each other 
and ring close as opposed to oligomerise. However, this was not the case with 
oligomers being almost exclusively produced in both cases. Dusselier et al. reported 
that H-beta zeolite could be used to give ‘shape selective catalysis’ of lactic acid 4 to 
lactide 6, as the reaction is thought to take place inside the zeolite cavity, which 
favours the ring formation.96 The zeolite reaction is also advantageous over the two-
step reaction in Scheme 2.8 as the catalyst is heterogeneous so does not introduce 
any harmful metal ions, such as tin, into the polymer which could have negative effects 
in biological applications. Also, unlike the two other methods, the zeolite reaction 
produced lactide that did not need any further purification.  
Several other reactions were carried out using H-beta zeolite (Table 2.3) which 
showed that it was important that the zeolite was calcined at 550°C before use, and 
that the reaction was carried out in toluene at 1.10 M.  





% isolated yield 
250°Ca Toluene 1.10 19 
550°Cb Toluene 1.10 34 
550°Cb Toluene 0.22 24 
550°Cb o-Xylene 1.10 impure 
aZeolite was held at 250°C under vacuum for 18 h 
bZeolite was heated in a furnace in air to 550°C over 6 h, held at 550°C for 6 h and then cooled 
back to room temperature over 6 h 
Reactions were carried out on 1.2 g lactic acid (85%, aq) and 0.5 g H-beta zeolite 
 
To try and further increase the yield from the zeolite reaction, the oligomers produced 
as a side product 19 were isolated and then hydrolysed back to lactic acid 4 for 
recycling. The isolation of the oligomers was achieved by extraction into water; the 
oligomers 19 all have free acid end groups making them water soluble, unlike the 
lactide 6 which extracts into the organic phase. After isolation, the aqueous phase 
was lyophilised and NMR analysis showed that a variety of oligomeric species and 
lactic acid 4 were present. The mixture was then heated to 180°C in water for three 
to four hours, with NMR analysis showing an increase in the lactic acid peak indicating 
hydrolysis of the monomers. The aim was to use this hydrolysis method to recycle the 
more precious deuterated lactic acid.  
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The optimised zeolite ring closing reaction was then carried out on lactic acid-d3 18, 
which did not show the same reactivity as the lactic acid. In toluene, the reaction was 
unsuccessful with no product formed. The reaction was then attempted in o-xylene, 
which did produce a new product peak by TLC. The product of this reaction was very 
impure, but there was a peak present in the 1H NMR spectrum at 5.00 ppm, which is 
at a similar position as the methine proton of lactide (Figure 2.6), however, the crude 
mixture proved difficult to purify by column chromatography.  
 
Figure 2.6 Evidence for lactide-d6 20 (top) from 1H NMR showing a singlet at ~5 ppm thought 
to correspond to the methine proton. This is at similar chemical shift to the methine proton of 
lactide 6 (bottom). 
Considering the difficulties encountered in the synthesis and purification of lactide-d6 
20, it was decided that this was not a viable route to producing a deuterated PLGA.  
2.2.2 H/D exchange 
As an alternative approach to introduce a carbon–deuterium bond into a PLGA 
monomer, an H/D exchange reaction was carried out on both cyclic monomers. Dos 
Santos et al. demonstrated H/D exchange on both lactide 6 and glycolide 7 via a high-
temperature solid-state catalytic isotope exchange process with maximum 
deuteration of 30% and 24% for lactide and glycolide respectively.107,108 The hope was 
to replicate this synthesis and introduce a high enough percentage of deuterium so 
that a polymer suitable for biological Raman imaging could be synthesised, with the 
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added advantage of not having to perform a ring closing reaction. The exchange 
reaction is shown in Scheme 2.9. 
 
Scheme 2.9 An H/D exchange reaction to produce deuterated cyclic monomers 21/22. R = 
CH3 (lactide 6) and R = H (glycolide 7). Reagents and conditions: i) Lindlar catalyst (5 wt%), 
D2 gas, 1 h, 90°C for glycolide, 100°C for lactide.  
For deuterated lactide 21, NMR spectroscopy could be used to calculate the extent of 
labelling by comparing the integral of the methine proton before and after deuteration, 
when the methyl protons are always set to 3.00 (Table 2.4).  
Table 2.4 Percentage deuteration of lactide calculated from 1H NMR. 
Condition CH3 integral CH integral % Deuteration 
Before deuteration 3.00 0.94 0.00 
1 h deuteration 3.00 0.93 1.06 
5 h deuteration 3.00 0.91 3.20 
 
The results in Table 2.4 show that low levels of deuteration had been achieved, 
however, mass spectrometry by electron ionisation indicated higher levels of labelled 
product. The relative abundancies of m/z 144 (unlabelled), 145 (mono-labelled) and 
146 (di-labelled) were 49.3, 31.5 and 6.3 respectively. 2H NMR of the isolated product 
21 confirmed that there was deuterium present, but the signal is very weak. The 
spontaneous Raman spectrum of the product shows a small, broad deuterium stretch 
at ~2160 cm-1 (Figure 2.7).  




Figure 2.7 Evidence for the deuteration of lactide by spontaneous Raman spectroscopy, λex 
785 nm (A) and 2H NMR (B). 
For glycolide 7, which only contains methylene protons, the percentage of deuteration 
could not be estimated by NMR, so mass spectrometry was used solely. The 
exchange reaction on glycolide seemed to be much less efficient, with the relative 
abundancies of m/z 116 (unlabelled) and 117 (mono-labelled) being 100.0 and 7.7 
respectively. Again, there were peaks present in the 2H NMR spectrum, but in the 
spontaneous Raman spectrum there was not a clear carbon-deuterium stretch (sharp 
peaks are due to interference from cosmic rays) (Figure 2.8). 
 
Figure 2.8 Analysis of deuterated glycolide by spontaneous Raman spectroscopy, λex 785 nm 
(A) and 2H NMR (B). 
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2.3 Routes to Deuterated Polymers 
2.3.1 Ring opening polymerisation 
2.3.1.1 Synthesis of PLGA 
PLGA was synthesised from lactide and glycolide using stannous octanoate as the 
catalyst and dodecanol as the co-initiator (Scheme 2.10). The reaction was carried 
out as a melt in the absence of solvent, as this can reduce reaction times and lead to 
a higher molecular weight polymer.  
 
Scheme 2.10 Synthesis of PLGA 8 via a tin catalysed ROP of lactide 6 and glycolide 7. 
Reagents and conditions: i) stannous octanoate (1 mol %), dodecanol (1 mol %), 120°C, 0.5 h.  
Glycolide 7 had a higher reactivity than lactide 6, probably due to the steric hindrance 
of the methyl group on lactide, so the starting ratio of the monomers were adjusted to 
~60 lactide: 40 glycolide to give ~50:50 PLGA 8. NMR spectroscopy is used to find 




















 × 100 
Equation 2.1 The percentage of PLA and PGA in the final polymer can be determined by NMR 
integrals.  




Figure 2.9 1H NMR spectrum of PLGA 8 synthesised with ROP where the peak integrals can 
be used to calculate the ratio of PLA and PGA.  
PLGA 8 was also characterised by spontaneous Raman spectroscopy, which shows 
characteristic peaks for CH2, CH3 and carbonyl bonds (C=O), but no peaks in the cell 
silent region (Figure 2.10). This highlights the need for bioorthogonal labels to be able 
to selectively image the polymer in the cell-silent region.  
 
Figure 2.10 Analysis of PLGA 8 with spontaneous Raman spectroscopy, λex 785 nm. 
2.3.1.2 Synthesis of PLGA-D 
ROP was employed to form deuterated PLGA from the labelled cyclic monomers 
whose synthesis is described in Section 2.2.2. Since the labelled lactide 21 showed 
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the most significant carbon-deuterium peak by spontaneous Raman (Figure 2.7), the 
PLGA synthesis was attempted with this lactide 21 and commercial, unlabelled 
glycolide 7. The ROP proceeded successfully and polymer was precipitated. Although 
the polymer did show some weak peaks in the 2H NMR, there were no C-D peaks 
apparent in the spontaneous Raman, so this polymer was not taken forward to further 
studies. 
2.3.2 Polycondensation polymerisation 
As described above, the cyclic deuterated lactide 21 formed via the H/D exchange 
reaction did not produce a strong enough deuterium signal when polymerised, 
probably due to the fact that the monomer was only ~3% deuterated. On the other 
hand, the lactic acid d3 18 synthesised via the alkylation route (Section 2.2.1) was 
100% deuterated. Considering the difficulties faced producing cyclic lactide from this 
deuterated monomer, an alternative polycondensation polymerisation route was 
explored.  
Polymers may be formed through condensation reactions where water is produced 
as a by-product. Several groups have reported syntheses of high molecular weight 
PLGA from lactic and glycolic acid by first dehydrating to form oligomers and then 
adding a tin catalyst to drive the formation of higher molecular weight polymers.109,110  
Deuterated PLGA was successfully synthesised using this approach from a mixture 
of commercial lactic acid 4 and glycolic acid 5, and the lactic acid-d3 18 synthesised 
in-house (Scheme 2.11). The reaction was set up in a round bottomed flask fitted with 
an air condenser packed with molecular sieves, in the hope that they would absorb 
the water produced. Since the boiling point of lactic acid is 122°C, the temperature 
was increased gradually from 100–150°C in the first step of the synthesis so as not 
to evaporate any of the lactic acid.  
 
Scheme 2.11 Synthesis of PLGA-D 23 via a polycondensation reaction. Reagents and 
conditions: i); 150°C, 8 h, ii); SnCl2, p-TSA, 180°C, 8 h.  
Although the polymerisation was successful, the precipitated polymer 23 was brown 
in colour, which resulted in issues when it was analysed by spontaneous Raman. The 
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polymer had a high background signal, and a large, broad peak at ~1800 cm-1, which 
was hypothesised to be due to the brown colour. Also, very low laser powers had to 
be used (<1%) or the signal would top out due to the high background.  
The synthesis in Scheme 2.11 was repeated, but using commercial lactic acid-d3, and 
this time the precipitated polymer was colourless, with Mn = 4553 Da and Ð = 1.84. 
When analysed by spontaneous Raman, there was still a high background but the 
polymer peaks, including carbon-deuterium peaks in the cell silent region, were 
observed (Figure 2.11).  
 
Figure 2.11 Analysis of PLGA-D 23 with spontaneous Raman spectroscopy, λex 785 nm. 
Although the Raman signal was weak, this polymer was taken forward to further 
experiments for making nanoparticles and carrying out SRS imaging. It was 
hypothesised that there were small amounts of impurity present in the in-house lactic 
acid-d3 18, which caused discolouration upon polymerisation and extended heating. 
The monomer could have been purified by distillation to remove these impurities, but 
this would have been difficult and low yielding on a small scale.  
 
2.4 Synthesis of PLGA-alkyne 
As mentioned in Chapter 1, alkyne tags are an alternative chemical group which 
produce peaks in the cell-silent region, and usually have a stronger Raman cross-
section than deuterium. An alkyne tagged analogue of PLGA (PLGA-alkyne 25) was 
synthesised by Dr Stefan Cairns.111  
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To introduce the alkyne functionality to PLGA, the telechelic properties of the polymer 
were exploited by carrying out a trans-esterification reaction, catalysed by stannous 
octanoate, with a five-membered 1,3-dioxolan-4-one ring bearing an alkyne 
functionality 24 (Scheme 2.12).  
 
Scheme 2.12 Synthesis of PLGA-alkyne 25. Reagents and conditions: i) Sn(oct)2, toluene, 
110°C, 24 h. Synthesis carried out by Dr Stefan Cairns.111 
Recent work has shown that 1,3-dioxolan-4-ones (DOX) are a versatile and 
sustainable family of monomers for ring opening polymerisation, and can often be 
synthesised from amino acids.112 There is no parent amino acid containing the alkyne 
functionality, so propargyl-DOX 24 was synthesised from propargyl bromide 26 and 
ethyl glyoxalate 27 in a zinc catalysed Barbier reaction, as previously reported 
(Scheme 2.13).113,114  
 
Scheme 2.13 Synthesis of propargyl α-hydroxy acid 29. Reagents and conditions: i); Zn, 
Et2O/THF, 0°C, 16 h, ii); HCl/H2O, 100°C, 24 h. Synthesis carried out by Dr Stefan Cairns.111 
To obtain the ring closed propargyl-DOX 24, the propargyl α-hydroxy acid 29, 
paraformaldehyde 30, and para-toluene sulfonic acid were dissolved in benzene and 
refluxed in a Dean-Stark apparatus to remove water, as previously reported,112 to give 
the desired product 24 in 66% yield (Scheme 2.14). 
 
Scheme 2.14 Synthesis of propargyl DOX 24. Reagents and conditions: i) para-TSA, 110°C, 
6 h. Synthesis carried out by Dr Stefan Cairns.111 
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Reaction of propargyl DOX 24 with pre-formed PLGA 8 gave rise to statistical 
distribution of the alkyne units throughout the polymer chain (Mn = 5900 Da, Ð = 1.88), 
with the incorporation confirmed in the diffusion ordered spectroscopy (DOSY) NMR 
(Figure 2.12).  
 
Figure 2.12 Analysis of PLGA-alkyne 25 with DOSY NMR. The polymer 1H peaks all have the 
same diffusion coefficient, which confirms that the alkyne units have been incorporated into 
the existing PLGA chain.  
The PLGA-alkyne 25 was then characterised by spontaneous Raman spectroscopy, 
and was found to have a single, sharp alkyne peak at 2128 cm-1 (Figure 2.13).  
 
Figure 2.13 Analysis of PLGA-alkyne 25 with spontaneous Raman spectroscopy showing a 
strong alkyne signal at 2128 cm-1, λex 785 nm. 
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The PLGA-alkyne 25 shows a very strong alkyne signal, with a much higher intensity 
than the multiple carbon-deuterium peaks in the PLGA-D 23 spectrum (Figure 2.11), 
making it an attractive candidate for further Raman studies.  
 
2.5 Conclusions 
In this chapter, the synthesis of unlabelled PLGA 8, along with the syntheses of 
bioorthogonally labelled PLGA-D 23 and PLGA-alkyne 25 are described. Two routes 
to produce deuterated monomers were investigated, an alkylation route with CD3I and 
an H/D exchange with deuterium gas. The H/D exchange approach gave very low 
levels of exchange, and the PLGA produced from these monomers did not show C-D 
peaks when analysed by spontaneous Raman. The alkylation route gave lactic acid-
d3 that was fully deuterated, but ring-closing this to the cyclic lactide-d6 proved difficult. 
A direct polycondensation polymerisation method, as opposed to ROP, was 
successfully used to synthesise PLGA-D from both commercial lactic acid-d3 and that 
synthesised in-house. However, the PLGA-D obtained from the in-house material was 
brown in colour and did not give a Raman signal. On the other hand, the commercial 
lactic acid-d3 produced a colourless polymer which produced multiple C-D peaks in 
the cell-silent region of the Raman spectrum. Scheme 2.15 shows a summary of the 
reactions attempted to produce PLGA-D. In addition, PLGA-alkyne was synthesised 
by Dr Stefan Cairns which produced a single, strong alkyne peak in the cell-silent 
region. Both of these polymers were taken onto further studies as candidates to 
synthesise NPs for SRS imaging.  
 




Scheme 2.15 Summary of reactions attempted to produce PLGA-D 23. Lactic acid-d3 18 was 
produced over five steps from bromoacetic acid 9, but ring closing to lactide-d6 20 was 
unsuccessful. A H/D exchange reaction was used to produce deuterated lactide and glycolide 
21/22, but the resulting polymer did not have a carbon-deuterium signal by spontaneous 
Raman. PLGA-D 23 was successfully synthesised by a polycondensation synthesis from 
commercial lactic acid-d3. 
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Chapter 3 Synthesis of Nanoparticles for Drug 
Delivery 
3.1 Introduction to Nanomaterials 
Nanomaterials are defined as ‘a material containing particles where one or more 
dimensions is in the size range 1–100 nm’, with these dimensions known as the 
nanoscale.115 There are various classes of nanomaterials including carbon based 
materials,116 metals,117 and organic polymeric nanoparticles (NPs), which will be the 
focus of this thesis (Figure 3.1).  
 
Figure 3.1 Examples of organic materials used to make nanoparticles. Biopolymers (e.g. 
alginate and chitosan), synthetic polymers (e.g. PLGA/PLA) and lipid-based materials (e.g. 
liposomes and micelles) are all commonly used to fabricate nanomaterials. 
Owing to the nanoscale size of these particles, they exhibit strikingly different physical 
and chemical properties to their bulk counterparts. Polymer nanoparticles are colloidal 
systems, have an extremely high surface area to volume ratio, and are governed by 
quantum mechanics, undergoing Brownian motion in suspension.118 These properties 
can be exploited for many scientific applications.  
3.1.1 Nanomaterials for drug delivery 
The use of nanomaterials in medical research is becoming increasingly popular as 
efforts to deliver more targeted and personalised treatments are realised.119–121 In both 
clinical and research settings, nanomedicines are being exploited for targeted drug 
delivery giving superior pharmacokinetic properties over a free drug, and 
diagnostics.122 In the case of biodegradable polymeric NPs, drug molecules can be 
incorporated into the polymer matrix and then as the polymer degrades in vivo, 
sustained release of the drug is achieved.94   
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3.1.2 Characterisation of nanomaterials 
3.1.2.1 Electron microscopy 
The invention of the electron microscope was vital for the discovery and 
characterisation of nanomaterials. In contrast to conventional light microscopy, 
electron microscopes focus a high-energy beam of electrons onto a specimen to 
achieve superior magnification and resolution. Light microscopy is limited by the 
diffraction of light to a resolution of around 200 nm,123 whereas electron microscopes 
are capable of resolving down to 0.1 nm,124 making them necessary for the 
visualisation of NPs. Both transmission electron microscopy (TEM) and scanning 
electron microscopy (SEM) are commonly used to characterise NP size and 
morphology.  
Figure 3.2 shows a comparison of PLGA NPs imaged by brightfield microscopy (A), 
TEM (B), and SEM (C). An advantage of brightfield microscopy is that the 
nanoparticles can be imaged in suspension, whilst for TEM and SEM the 
nanoparticles must be dried as part of the sample preparation. For TEM, a drop of the 
nanoparticle suspension is dried on a copper grid at room temperature, and for SEM 
the nanoparticles are dried in an oven before sputter-coating with a layer of gold to 
allow elucidation of 3D particle morphology. A disadvantage of characterising 
nanoparticles in a dried state is that they may aggregate upon evaporation of the 
water, meaning that the image obtained is not representative of the particles in 
suspension. However, for sizing the nanoparticles, it is necessary to use electron 
microscopy. Recently, advances in cryogenic electron microscopy have shown that 
freezing the NPs in suspension allows preservation of the particle distribution.125 




Figure 3.2 Comparison of different microscopy techniques available for nanoparticle 
characterisation. A) Brightfield microscopy, scale bar = 5 µm; B) TEM, scale bar = 500 nm; C) 
SEM, scale bar = 500 nm.  
3.1.2.2 Light scattering techniques 
Nanoparticles move around in suspension in a so called ‘random walk’ known as 
Brownian motion. This property can be exploited by light scattering techniques to 
measure a particle’s hydrodynamic diameter, defined as a hard sphere diffusing at 
the same rate of the particle of interest, using the relationship defined in the Stokes-
Einstein equation (Equation 3.1). Two light scattering techniques will be discussed in 
this chapter, dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA), 
and both measure the velocity of Brownian motion, known as the diffusion coefficient 





Equation 3.1: The Stokes-Einstein equation. Where dH = hydrodynamic diameter, k = 
Boltzmann’s constant, T = temperature, η = viscosity of the dispersant and D = diffusion 
coefficient.  
A limitation of light scattering is that hydrodynamic diameter is measured, not absolute 
particle size, and this assumes that the particle is spherical. Equation 3.1 also 
highlights the importance of knowing the temperature and viscosity of the dispersant 
when taking measurements.  
DLS measures the hydrodynamic diameter from a bulk solution of particles and also 
provides a number for the dispersity of the NP suspension, the polydispersity index 
(PdI). PdI is scaled between zero and one, with a higher PdI corresponding to a more 
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disperse sample. A disadvantage of DLS is that size results can be skewed by the 
presence of a small number of large particles since light scattering intensity is 
proportional to particle diameter to the power of six.127  
In contrast to DLS, NTA tracks individual particles and measures their Brownian 
motion, and thus provides more detailed information about the size distribution of the 
sample.128 Figure 3.3 shows the NTA experimental set-up. NPs are suspended in a 
solvent and injected into a sample chamber. A monochromatic laser is then shone at 
the sample, and the light scattered by the particles is detected by a camera operating 
at 30 frames per second to visualise the particles and measure their Brownian 
motion.129,130 A further advantage of NTA is that because individual particles are 
tracked and counted in a known volume, particle concentration can also be estimated.  
 
Figure 3.3 Nanoparticle tracking analysis. A sample of NPs suspended in liquid is irradiated 
with a laser, and the light scattered by the NPs is detected by a camera, allowing the NPs to 
be tracked.129 
 
3.2 Nanoparticle Synthesis 
There have been many methods for NP fabrication reported in the literature, and the 
choice of synthesis will depend on the desired application of the resulting NPs, for 
example, the physical properties of the drug payload to be encapsulated and 
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delivered.131 These methods can generally be divided into emulsion-based techniques 
where shear force is used to create nanodroplets, and techniques where NPs 
spontaneously form without the need for an emulsion. 
3.2.1 The emulsification-evaporation method 
The emulsification-evaporation method is one of the most commonly used techniques 
for the synthesis of NPs for drug delivery because of its ability to encapsulate a wide 
range of drug payloads from small molecules to proteins.132 A visual schematic of the 
standard emulsification-evaporation method used in this work to produce blank (with 
no drug payload) NPs is shown in Figure 3.4. 
The polymer dissolved in dichloromethane (DCM), an organic solvent that is not 
water-miscible, was emulsified with an aqueous phase containing an emulsification 
agent (poly(vinyl alcohol)) and a surfactant (sodium dodecyl sulphate), to form a 
stable oil-in-water emulsion. This emulsion was then stirred at room temperature 
overnight to allow complete evaporation of the DCM, resulting in hardened polymer 
NPs that could be collected by centrifugation. 
 
Figure 3.4 The emulsification-evaporation method. The polymer dissolved in an organic 
solvent is emulsified with an aqueous phase containing an emulsification agent and a 
surfactant to form a stable emulsion. The organic solvent is then evaporated to form hardened 
NPs. 
The process shown in Figure 3.4 above can be used to encapsulate hydrophobic 
drugs by simply adding them to the organic phase with the polymer. In order to 
encapsulate hydrophilic drugs, including protein and peptide therapeutics, the 
process is modified to a double emulsion method. The protein, dissolved in an 
aqueous buffer, is first emulsified with the polymeric organic phase. This primary 
emulsion is then immediately emulsified with the secondary aqueous phase, 
containing the emulsification agent, to form a water-in-oil-in-water emulsion.  
The emulsification-evaporation conditions were optimised for controlled NP formation, 
and to limit particle aggregation. 
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3.2.1.1 Emulsion formation 
The method of forming the oil-in-water emulsion was found to be critical for controlling 
the size of the resulting particles. Preliminary experiments used a vortex to form the 
emulsion, and this resulted in large microparticles being formed. The presence of 
these larger particles was evident as there was sedimentation in the emulsions; larger 
particles in suspension do not undergo Brownian motion as their larger mass means 
that gravity, resulting in sedimentation, is the dominant force. The size of these 
particles was variable, and determined to be between 0.5 and 5 µm by TEM (Figure 
3.5 A). 
In contrast, when the emulsion was formed with a probe tip sonicator, where the 
sonicator is submerged in the liquid, a stable emulsion of NPs was formed. The 
formation of these NPs was also confirmed by TEM (Figure 3.5 B). 
 
Figure 3.5 TEM analysis of micro and nanoparticles. A) When a vortex was used to create the 
emulsion, microparticles were formed. B) A probe-tip sonicator formed nanoparticles. Scale 
bars = 2 µm. 
3.2.1.2 Evaporation time 
Evaporation time was also found to be an important variable to ensure the complete 
evaporation of DCM. Issues with aggregation were encountered when the 
evaporation time was not long enough, as residual DCM can cause the NPs to form 
aggregates when centrifuged.133 To find the time needed for complete DCM 
evaporation, the emulsion was sampled at regular time points, and any residual DCM 
was extracted into deuterated chloroform before analysing with 1H NMR. 
Figure 3.6 shows that the majority of DCM had evaporated after two hours, however, 
an expanded view of the NMR showed that there was a small amount of DCM 
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remaining after six hours. The emulsions were therefore stirred overnight to ensure 
complete DCM evaporation.  
 
Figure 3.6 Evaporation of DCM. The emulsion was sampled over time and analysed with 1H 
NMR for the presence of DCM. Inset shows an expanded view of the 6 hour sample.  
3.2.1.3 Centrifugation time 
Particle aggregation was an ongoing problem, even with the extended evaporation 
times. NP aggregation is irreversible, as opposed to agglomeration in which loose 
interactions can be reversed by vortexing (Figure 3.7).134 
 
Figure 3.7 Nanoparticle aggregation is irreversible. Particles in suspension (A) can join 
together into reversible agglomerates (B) or irreversible aggregates (C). 
Most literature preparations for PLGA NPs describe washing the particles three times 
with deionised water, which involves repeated centrifugation cycles and resuspension 
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in fresh water. When trying to replicate this protocol, it was found that after one 
centrifugation cycle, the NP pellet could be resuspended with vortexing, however, with 
a further cycle of centrifugation, the NP pellet would not go back into suspension. This 
indicates that the NPs had formed irreversible aggregates.  
In an attempt to limit this aggregation, different centrifugation speeds were 
investigated for NP isolation. A NP emulsion was formed using the standard 
emulsification-evaporation method and, after an overnight evaporation, the NP 
emulsion was split into nine samples and each was centrifuged for ten minutes at 
speeds between 2,408 and 16,278 × g. The NP pellets were then resuspended in 
water, and analysed by DLS for particle size and PdI (Figure 3.8).  
 
Figure 3.8 Investigation of optimum centrifugation speed. NPs were centrifuged for ten 
minutes at different speeds and then their particle size and PdI were measured with DLS. 
Three measurements were taken for each sample, error bars show standard error of the mean.  
Figure 3.8 shows that particle size decreases with increasing centrifugation speed 
until 6,164 × g, where it begins to increase again. The hypothesis for this trend is that 
the lower speeds do not have enough centrifugal force to pellet smaller particles, 
leading to an increase in the average size, and that higher centrifugation speeds 
cause particle aggregation. The PdI is fairly constant across all conditions at ~0.15, 
which can be classed as a monodisperse sample.135 6,164 × g was chosen as the 
optimum centrifugation speed for the NPs as it gave the smallest particle size. 
Furthermore, at this speed the particles could be centrifuged twice and still go back 
Synthesis of Nanoparticles for Drug Delivery 
59 
 
into suspension, however, a further centrifugation cycle still caused aggregation. The 
NPs were therefore washed only once with deionised water.  
3.2.1.4 Lyophilisation 
Many protocols lyophilise NPs for long-term storage, as aggregation usually increases 
over time in an aqueous suspension. To investigate the aqueous stability of the NPs, 
the particle size was measured by DLS when the NPs were freshly made (day zero) 
and then two, six and ten days after this (Figure 3.9). This shows that the PLGA-
alkyne NPs are stable over ten days, with no significant difference in particle size 
between day zero and day ten. However, the PLGA-D NPs do show a significant 
increase in size over time, indicating that they are aggregating and lyophilisation 
should be explored.  
 
Figure 3.9 Aqueous stability of PLGA-D and PLGA-alkyne NPs over time. Particle size was 
measured in triplicate by DLS at each time point. Error bars show standard error of the mean, 
*: p <0.05, n.s.: p >0.05, one-way ANOVA. 
Lyophilisation of PLGA NPs produced by the emulsification-evaporation method was 
achieved by resuspending the NP pellet in water, before freezing in liquid nitrogen 
and lyophilising overnight to give a white powder. However, this powder proved 
difficult to get back into suspension even after repeated vortexing, indicating that the 
particles were aggregated.  
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NPs can undergo irreversible aggregation caused by freezing stress, so 
cryoprotectants are often added to the formulation before lyophilisation.136,137 Sucrose 
was investigated as a cryoprotectant in an attempt to prevent aggregate formation. A 
standard NP suspension was split into five samples, and one was left non-lyophilised 
as a control. The other four samples were lyophilised in 0, 1, 2 and 3% sucrose (w/v) 
in water. The lyophilised powders were then resuspended in water, and their particle 
size analysed by DLS, and compared to the non-lyophilised control.  
Figure 3.10 shows that the non-lyophilised control had an average particle size of 
~150 nm. When the NPs were lyophilised in water only, DLS confirmed that 
aggregates were forming as the average particle size increased dramatically to ~380 
nm, with a large variability between measurements. The addition of 1, 2 or 3% sucrose 
seems to be successful in protecting the NPs from freeze damage, as the 
resuspended NPs had a very similar particle size to that of the control.  
Although DLS showed that NPs lyophilised with sucrose had a similar average particle 
size to a non-lyophilised sample, cell death was observed when these NPs were used 
in biological experiments, so the NPs were prepared freshly every time.  
 
Figure 3.10 Lyophilisation of NPs with sucrose. NP samples were lyophilised with 0, 1, 2 and 
3% sucrose and their particle size compared to a non-lyophilised control by DLS. Three 
measurements were taken for each sample, error bars show standard error of the mean.  
3.2.1.5 Optimised protocol 
The optimised emulsification-evaporation protocol, using a probe tip sonicator to form 
the emulsion, evaporating the DCM overnight, and centrifuging at 6,164 × g for ten 
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minutes, was used to synthesise NPs from PLGA 8, and also the two bioorthogonally 
labelled polymers (PLGA-D 23 and PLGA-alkyne 25). DLS was used to compare the 
properties of the NPs produced from these three polymers (Figure 3.11). The average 
particle size and PdI for the three polymers are listed in Table 3.1. 
Table 3.1 Particle size and PdI of PLGA, PLGA-D and PLGA-alkyne NPs. 
Polymer Particle size (nm) PdI 
PLGA 8 147 0.10 
PLGA-D 23 180 0.15 
PLGA-alkyne 25 129 0.17 
 
 
Figure 3.11 DLS characterisation of NPs. The optimised emulsification-evaporation method 
was used to synthesise PLGA, PLGA-D and PLGA-alkyne NPs and their average particle sizes 
were 147, 180 and 129 nm respectively. Spectra are normalised between 0 and 1 and offset 
for clarity. 
The data in Table 3.1 and Figure 3.11 show that the emulsification-evaporation 
method can be used to form NPs of comparable size and dispersity from PLGA 8 and 
the two bioorthogonally labelled analogues PLGA-D 23 and PLGA-alkyne 25. The 
NPs are all less than 200 nm in size, meaning that they have a high chance of entering 
cells by either endocytosis or phagocytosis.138,139  
All of the DLS characterisation had been carried out in water, but since these NPs 
would be added to cells and tissues, their particle size was also investigated in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf 
serum. Figure 3.12 shows the particle size distribution obtained from the DLS analysis 
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of PLGA-alkyne NPs, from the same batch, analysed in both water and DMEM. This 
shows that the size of the NP peak is unchanged at ~190 nm. In the trace for the NPs 
in media, there are two other smaller peaks which are also present in the media blank, 
presumably due to proteins and serum.  
 
Figure 3.12 Analysis of NP size in water and media. NPs were produced from PLGA-alkyne, 
split into two and then resuspended in either water or DMEM, and their particle size analysed 
by DLS. Spectra are normalised between 0 and 1 and offset for clarity. 
In Figure 3.12, the NPs suspended in water also shows that there is a larger 
aggregate of NPs at ~6000 nm. As mentioned in Section 3.1.2.2, large particles are 
disproportionally represented in DLS, since light scattering is proportional to diameter 
to the power of six, so this could be due to only a small amount of aggregated particles. 
DLS can also suffer from contaminants in the samples such as dust, and this can be 
minimised by pre-filtering samples through 0.45 µm filters.  
3.2.2 The nanoprecipitation method 
The nanoprecipitation method is an alternative NP synthesis which was also explored 
for PLGA NPs. The polymer was dissolved in a water miscible solvent (in this case 
acetonitrile), and upon dropping this solution into an aqueous phase, NPs 
spontaneously formed in a process known as solvent diffusion.140 The acetonitrile 
could then be removed in vacuo to yield the hardened NPs. Advantages of this 
method over the emulsification-evaporation method are that no shear force has to be 
applied to form the emulsion, which could alter the structure of protein therapeutics 
being encapsulated, and no surfactants or stabilisers have to be added to the aqueous 
phase. A disadvantage of the nanoprecipitation method is that it is difficult to 
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encapsulate hydrophilic drugs in this way, although a two-step nanoprecipitation 
method for protein loading has been described by Morales-Cruz et al.141 
The NPs produced by the nanoprecipitation method were isolated by centrifugation, 
resuspended in water and analysed by DLS and TEM (Figure 3.13).  
 
Figure 3.13 Characterisation of NPs produced with the nanoprecipitation method. A) DLS 
showed that the average NP size was 121 nm and the PdI was 0.07. B) TEM confirmed the 
size and monodispersity of the NPs. Scale bar 500 nm. 
The NPs produced by the nanoprecipitation method had a smaller particle size 
(~120 nm), and with a PdI of 0.07 could be considered very monodisperse. However, 
because of the popularity of the emulsification-evaporation method in the literature for 
encapsulating a wide range of drug payloads, this method was taken forward to 
produce NPs for further studies.  
 
3.3 Nanoparticle Concentration 
Since the NPs produced were going to be used for biological experiments, it was vital 
to reliably know the concentration of the NPs in order to have reproducible 
experiments. In the optimised NP preparation protocol, the polymer was weighed out 
accurately, so a concentration of the polymer solution was known. However, it would 
be unreliable to assume full conversion of all the polymer to NPs, and the 
centrifugation and removal of the supernatant during the isolation and washes could 
also contribute to loss of the NPs. 
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Often, NPs are lyophilised so that the powder can be weighed out to resuspend the 
NPs into a suspension of known concentration. The lyophilisation protocol described 
in Section 3.2.1.4 used sucrose as a cryoprotectant, but this seemed to cause toxicity 
when these particles were incubated with cells, meaning that this technique could not 
be used to find NP concentration. Alternative methods of finding NP concentration 
were investigated which could be used to measure each batch of NPs.  
3.3.1 Concentration by absorption 
The NP suspension in water had a UV absorbance at 220 nm due to the carbonyl 
bonds in the polymer backbone. Absorbance is related to concentration in a linear 
fashion according to the Beer-Lambert Law,142 so it was attempted to produce a 
calibration curve of the absorption of known NP concentrations. In triplicate, PLGA 
NPs were prepared using the optimised emulsification-evaporation method and were 
then lyophilised, without sucrose, to find the weight of the dry NPs. The NPs were 
then resuspended in water and each of the three samples was analysed by UV 
spectroscopy to find the absorbance at 220 nm of the NPs at 600, 300, 150 and 
75 µg mL-1. The standard curve produced is shown in Figure 3.14. 
 
Figure 3.14 Concentration of PLGA NPs by absorption at 220 nm. In triplicate, NPs were 
prepared and lyophilised before resuspending in water where known concentrations were 
analysed for absorbance at 220 nm. Three technical replicates were taken for each value and 
then the nine values were pooled to find the mean. Error bars show standard error of the mean. 
R2 = 0.997.  
Figure 3.14 shows that there is a linear relationship between A220 and concentration 
for the PLGA NPs which could be used to find the concentration of an unknown 
sample. However, when the experiment was repeated with PLGA-alkyne NPs, the 
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relationship was not linear, so could not be used to find the concentration of an 
unknown sample. This method of finding NP concentration was therefore not pursued 
further.  
3.3.2 Concentration by nanoparticle tracking analysis 
As discussed in Section 3.1.2.2, NTA is another way of finding particle concentration 
as it tracks individual particles in a known volume of solvent. NPs produced from all 
three polymers (PLGA 8, PLGA-D 23 and PLGA-alkyne 25) were analysed by NTA, 
which gave their particle size distribution and equivalent concentrations in 
particles mL-1 (Figure 3.15). The particle size distribution data is much more detailed 
than that obtained from DLS (Figure 3.11), because individual particles are being 
tracked instead of a measurement being taken from the bulk suspension. This makes 
NTA highly suited to analysing polydisperse samples, or samples with aggregates. 
To give more accurate NP concentration data, the samples were diluted until in the 
optimum range of 1–8 × 108 particles mL-1 was reached, as recommended by the 
manufacturer. As the tracks of individual particles are recorded to measure Brownian 
motion, having too many particles in the field of view makes it harder to resolve 
different tracks. On the other hand, having too few particles will lead to statistically 
unreliable results.  
The concentrations of NPs synthesised from 10 mg of the PLGA 8, PLGA-D 23 and 
PLGA-alkyne 25 polymers are listed in Table 3.2. The yield of NPs obtained from the 
PLGA-alkyne polymer 25 is significantly higher than that obtained from PLGA 8 and 
PLGA-D 23. One reason for this could be the increased hydrophobicity of PLGA-
alkyne, meaning that it will have a higher solubility in DCM. During the emulsification-
evaporation process, the polymer dissolved in DCM is mixed with an aqueous phase 
(Figure 3.4). Any polymer not fully soluble in DCM could partition into the aqueous 
layer, causing a loss of yield of the NPs. Using polymer with too low a molecular 
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Table 3.2 Concentration of NPs produced from 10 mg of PLGA, PLGA-D and PLGA-alkyne. 
Polymer Concentration (× 109 particles mL-1) 
PLGA 8 13.6 
PLGA-D 23 7.4 
PLGA-alkyne 25 42.6 
 
 
Figure 3.15 Analysis of NPs with NTA. A) Particle size distributions are obtained for PLGA 
(black), PLGA-D (red) and PLGA-alkyne (blue) NPs. B) Representative images obtained from 
the NTA camera of the three types of NPs. The NPs are visualised by the way they scatter 
light allowing their Brownian motion to be tracked, which is proportional to their size.  
 
3.4 Nanoparticle Targeting 
NPs are often targeted in a passive way, for example to tumours, where the gaps 
between tight junctions in blood vessels around the tumour and an increased 
secretion of permeability factors leads to accumulation of NPs, known as the 
enhanced permeation and retention effect.143 NPs can also be modified with targeting 
ligands on their surface with the aim of increasing drug efficacy, and reducing off-
target effects. Examples of active targeting ligands are sugars, peptides and 
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antibodies (Figure 3.16),144 and various strategies can be employed to attach them to 
the surface of the NPs.  
 
Figure 3.16 Nanoparticle targeting strategies. Drug loaded NPs can be targeted with 
antibodies, sugars, peptides and folate to direct them to a certain cell-type. Image created with 
Biorender.com. 
Antibodies are an obvious choice of targeting ligand because of their exquisite 
specificity of binding for their target antigen, whereas sugars are important for 
targeting cell surface receptors. Peptides and folate can be used to target cancer cells, 
which over-express certain factors.145,146 As well as targeting, peptides can also 
enhance cell permeability of NPs.147 Even with targeting ligands, NPs can still interact 
with off-target cells. Recently, Figueroa et al. designed virus mimetic NPs where two 
binding interactions are needed to trigger endocytosis of the NPs, giving superior 
cellular selectivity.148  
3.4.1 Avidin-lipid conjugates 
Previous work in the Williams group used PLGA NPs with surface antibodies to the 
neural / glial antigen 2 (NG2) protein to specifically target them to OPCs.20 
Conjugation of the NG2 antibody to the NP surface was achieved by exploiting the 
avidin-biotin binding capabilities. Avidin is a tetrameric protein that can bind four 
molecules of the small molecule biotin with extremely high affinity (Kd = 1.3 × 10-15 
M).149 Avidin-lipid conjugates were synthesised as described by Park et al.,150 and 
were then added into the NP preparation. The hypothesis is that the lipid tail will bury 
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into the hydrophobic NP, leaving the avidin on the surface which can then bind 
biotinylated NG2 antibody, which is commercially available.  
It was attempted to replicate this protocol so that surface avidin could be conjugated 
to the surface of the Raman labelled NPs. Palmitic acid 31, a 13-carbon long 
carboxylic acid, was first activated as its N-hydroxysuccinimide (NHS) ester 33 to 
increase its activity towards the ε-NH2 of lysine residues on avidin (Figure 3.17 A)  
 
Figure 3.17 Formation of avidin-lipid conjugates. A) Synthesis of NHS-palmitic acid 33. 
Reagents and conditions: i) DCM, triethylamine, bis(2,5-dioxopyrrolidin-1-yl) carbonate 32, rt, 
8 h. B) Structure of avidin with lysine residues highlighted in green. PDB 1VYO. C) Lysine 
conjugation, where the NHS-palmitic acid reacts with a free amine to form an amide bond with 
the protein. Reagents and conditions: ii) NHS-palmitic acid 33 (10 eq.) 1 M HEPES pH 8, 0.2% 
sodium deoxycholate, ~24 h. D) Reaction monitoring with UPLC. NHS-palmitic acid was 
incubated with avidin, and the avidin peak was observed to decrease over time by UPLC. 
However, no new product peak was seen emerging.   
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The NHS-palmitic acid 33 was then incubated with avidin in a ten-fold molar excess, 
in the hope that this activated NHS ester would react with surface accessible lysine 
residues (Figure 3.17 B) and conjugate the lipid chain through an amide bond (Figure 
3.17 C).  
The reaction was monitored by ultra-performance liquid chromatography (UPLC) and 
the avidin peak could be seen reducing over time, but no new product peak was 
clearly seen (Figure 3.17 D). The reaction was found to be unsuccessful without the 
addition of the surfactant sodium deoxycholate, which was needed to disrupt 
unreactive micelles of NHS-palmitic acid thought to form in the aqueous buffer.  
The success of this conjugation reaction was debatable, since no product peak was 
seen appearing over time on the UPLC trace. Analysis of the modified protein by mass 
spectrometry and gel electrophoresis was also inconclusive. The modified avidin band 
was similar to native avidin in the gel electrophoresis, and the modified avidin gave 
very low signal in the mass spectrometry. The NHS-palmitic acid 33 was added in a 
ten-fold molar excess, so it is possible that multiple labelling events could take place 
on different protein molecules producing a heterogeneous product that is hard to 
analyse. However, the solubility of the avidin-lipid conjugates was also thought to be 
a problem as precipitation was observed in the reaction mixture over time. The 
addition of lipid chains to the protein would decrease its hydrophilicity, so the solubility 
in HEPES buffer would be expected to decrease. Addition of low levels of dimethyl 
sulfoxide (DMSO) to the reaction mixture did not seem to help with the precipitation, 
and analysis of the protein concentration before and after the reaction (Nanodrop, 
A280) confirmed that the concentration decreased.  
Before adding the avidin-lipid conjugates to the NP synthesis, they were dialysed 
against 1 M HEPES to remove excess NHS-palmitic acid 33 and the sodium 
deoxycholate. To incorporate the avidin-lipid conjugates into the NPs, the standard 
emulsification-evaporation method was followed (Section 3.2.1), but with addition of 
the avidin-lipid conjugates to the aqueous phase. During the emulsion formation, the 
avidin-lipid conjugates should position themselves with the hydrophobic lipid tail 
pointing into the NP centre, leaving the avidin on the NP surface (Figure 3.18).  




Figure 3.18 Incorporation of avidin lipid conjugates into NPs. 
3.4.2 Biotin horseradish peroxidase assay 
In order to check if there was surface avidin on the NPs capable of binding biotin, a 
colorimetric assay was carried out using biotinylated horseradish peroxidase (biotin-
HRP). The biotin binding affinity of NPs prepared in the presence of avidin (Figure 
3.20 A) or avidin-lipid conjugates (Figure 3.20 B) was compared to standard NPs 
prepared without any avidin. The NPs were firstly all analysed by NTA to determine 
their concentration so that the same number of particles (2 × 109 particles mL-1) could 
be used for each condition.  
The NPs were incubated with biotin-HRP for before isolating the NPs by centrifugation, 
and washing once with PBS to remove residual biotin-HRP. 3,3’,5,5’-
Tetramethylbenzidine (TMB) 34 was then added to the NPs which is an aromatic 
compound that produces a blue colour in the presence of peroxidase, and turns yellow 
upon acidification (Figure 3.19).151 The NPs were incubated with TMB before the 
addition of 1 M hydrochloric acid which caused the samples to turn yellow, and their 
absorbance was measured at 450 nm (A450). A higher A450 value corresponds to more 
bound biotin HRP, which in turn indicates more surface avidin on the NPs. 




Figure 3.19 The biotin-HRP assay for quantification of surface avidin. NPs were incubated 
with biotin-HRP which will bind to avidin. After washing the NPs, TMB 34, which acts as a 
hydrogen donor, was then added which produces a blue charge transfer complex in the 
presence of HRP. Acidification with 1 M HCl trapped the complex, resulting in a yellow colour 
that could be analysed by UV spectroscopy at 450 nm. 
There was no significant increase in A450 between either the avidin or avidin-lipid NPs 
and the control NPs, indicating there was no avidin on the NP surfaces. The control 
NPs (no avidin) had an A450 value of ~3 showing that the assay has a high background, 
probably caused by small amounts of residual biotin-HRP that were not removed by 
the wash step. The A450 values obtained from these experiments are listed in Table 
3.3. When a control was carried out of the assay without the addition of biotin-HRP, 
no blue or yellow colours were observed. 
3.4.3 Chemical conjugation of avidin 
Instead of relying on avidin-lipid conjugates, two chemical reactions were explored to 
conjugate avidin to a preformed NP through a covalent bond. 
3.4.3.1 Carbamate formation 
The PLGA 8 and PLGA-alkyne 25 polymers used to produce the NPs have a free 
alcohol on their end groups. In an attempt to conjugate avidin to these alcohol groups, 
the amines on the avidin were first activated with 1,1-carbonyldiimidazole so that they 
could then react with the NP alcohol groups to form a carbamate bond (Figure 3.20 
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C). Padiya et al. reported an imidazole carbonylation in water on a variety of 
substrates, and these conditions were replicated with avidin (Scheme 3.1).152 
 
Scheme 3.1 Conjugation of avidin through a carbamate bond. Amide groups on avidin were 
first activated with 1,1-carbonyldiimidazole before reacting with the OH end groups on NPs to 
form a carbamate. Reagents and conditions:  i) 1,1-carbonyldiimidazole, PBS, 0 °C, 1 h; ii) 
NPs, 0 °C, 1 h then 0 °C – rt over 1 h. 
The biotin-HRP assay was repeated with these NPs, but again, no increase in biotin 
binding was observed over the control NPs. These results are listed in Table 3.3. 
3.4.3.2 Copper catalysed azide alkyne click reaction (CuAAC) 
The CuAAC reaction is a widely used bioorthogonal reaction used to conjugate labels 
to biomolecules in a biological environment.153 It involves the reaction of an alkyne 
and an azide to form a triazole bond. One of the bioorthogonal polymers (PLGA-
alkyne 25) contains terminal alkynes that could be available for click reactions. It was 
attempted to ‘click’ biotin azide onto preformed PLGA-alkyne NPs so that avidin could 
then bind to this biotin (Figure 3.20 D). Avidin is tetrameric, so it would still be possible 
to bind the biotinylated NG2 antibody onto another one of avidin’s binding sites.  
Copper sulphate, sodium ascorbate and tris(3-hydroxypropyltriazolylmethyl)amine 
(THPTA), a water soluble ligand,153 were first stirred in water to reduce the copper, 
before the addition of biotin-azide and PLGA-alkyne NPs to initiate the click reaction. 
The resulting NPs were then resuspended in a solution of avidin in PBS, and were 
stirred overnight at room temperature to allow conjugation of avidin Scheme 3.2.  




Scheme 3.2 Conjugation of biotin azide to NPs through a CuAAC reaction. Reagents and 
conditions: i) Copper sulphate, sodium ascorbate, tris(3-hydroxypropyltriazolylmethyl)amine, 
water, rt, 15 min; ii) biotin-PEG3-azide conjugate, PLGA-alkyne NPs, water, rt, 4 h; iii) isolated 
NPs, avidin, PBS, rt, 18 h.  
A summary of all targeting reactions are shown below in Figure 3.20. 
 
Figure 3.20 Summary of NP targeting strategies. A) Surface deposition of avidin. Reagents 
and conditions: i) NPs, avidin, rt, 18 h. B) Avidin lipid conjugates. Reagents and conditions: ii) 
Standard emulsification-evaporation method with avidin lipid conjugates added to the aqueous 
phase. C) Carbamate conjugation of avidin. Reagents and conditions: iii) 
1,1-carbonyldiimidazole, PBS, 0 °C, 1 h; iv) NPs, 0 °C, 1 h then 0 °C – rt over 1 h. D) v) Copper 
sulphate, sodium ascorbate, tris(3-hydroxypropyltriazolylmethyl)amine, water, rt, 15 min; vi) 
biotin-PEG3-azide conjugate, PLGA-alkyne NPs, water, rt, 4 h; vii) isolated NPs, avidin, PBS, 
rt, 18 h.  
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Again, analysis of these NPs with the biotin-HRP assay showed that there was no 
increase in biotin binding over control NPs (Table 3.3). The reaction could have been 
unsuccessful because the hydrophobic alkyne groups would most likely be pointing 
towards the inside of the NP and therefore inaccessible to react with biotin azide. 
Table 3.3 Biotin-HRP assay results from all the targeting strategies attempted. For each 
sample of the NPs, the assay was carried out in triplicate and the A450 shown is the average.  






















In this chapter, the formation of polymeric NPs has been described by both the 
emulsification-evaporation and nanoprecipitation methods. Optimisation of the 
emulsification-evaporation method revealed the best emulsification method, 
evaporation time and centrifugation speed to produce particles of ~150 nm and low 
dispersity from PLGA 8, PLGA-D 23 and PLGA-alkyne 25 polymers. Because of the 
tendency of the PLGA-D NPs to aggregate over time, it was decided to make them 
fresh before every biological experiment. The NP concentration could be found by 
analysing with NTA, which is vital for the reproducibility of the biological experiments 
described in Chapter 4. It was found through analysis by DLS and NTA that the 
bioorthogonal polymers PLGA-D and PLGA-alkyne produced NPs with comparable 
properties to the FDA approved PLGA NPs.  
Various methods were investigated to conjugate avidin to the surface of the NPs so 
that a biotinylated targeting antibody could be attached. However, it was found that 
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avidin-lipid conjugates, and attempts to covalently bind avidin to the NP surface 
through carbamate and triazole bonds, did not produce significantly higher biotin 
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Chapter 4 Raman Imaging of Bioorthogonal 
Nanoparticles 
4.1 Introduction  
Imaging drug delivery systems in a biological environment is of vital importance to 
elucidate their uptake, mode of action and ultimate fate. In this chapter, the 
bioorthogonally labelled NPs prepared in Chapter 3 were administered to a number 
of biological models of the brain, and the behaviour of the NPs was investigated by 
imaging them with SRS microscopy. 
4.1.1 Models of the brain 
In order to study the effects of a drug or treatment on the brain, biological models 
mimicking the brain, and various disease states, have been developed including 
single cells, organoids, brain tissue slices and whole animal models.  
4.1.1.1 Cell culture 
Cell culture is one of the simplest ways of modelling the effects of a treatment to brain 
cells.154 Immortal cell lines are often used as they are easy to culture, but these are 
transformed to allow their extended artificial culture over a long period, which means 
that they frequently develop different behaviour to their in vivo counterparts. The 
misidentification or contamination of cell lines can also lead to problems.155 In contrast, 
primary cells are isolated from fresh tissue and thus retain more in vivo characteristics 
and provide a more realistic model, but can only be cultured for a limited time.156 Cell 
cultures are usually grown 2D on a flat surface, but can also been grown in 3D cellular 
aggregates called spheroids, which can give a more realistic picture of, for example, 
a tumour.157  
To test the intracellular Raman activity of the NPs, primary rat microglia were utilised 
as proof of principle cells. Microglia are part of the immune response in the brain, and 
act as phagocytes to engulf foreign objects.2 It was thought that microglia would be 
likely to internalise the NPs and allow imaging.158 The microglia used were isolated 
from postnatal rat pups before every experiment.  
4.1.1.1 Ex vivo slice culture 
A disadvantage of cell culture experiments is that the cells are grown in a 2D 
environment on a dish, which is not representative of their in vivo state. The ex vivo 
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culture of brain slices has been used to bridge the gap between cell culture and whole 
organism studies.159,160 In this way, individual cells retain a similar tissue 
microenvironment as they would in a living organism. Slice cultures are a much more 
economical and high-throughput way of studying the effects of a drug on the brain 
compared to using live mice, and have been used as a screening platform.161 Samples 
of tissue from human brains obtained during surgery have also been sliced and 
cultured for up to two weeks to provide a model for glioblastoma.162  
4.1.1.1 In vivo studies 
Moving on to study the effects of research in live animals is vital for understanding the 
mode of action of the treatment in a whole organism. Cell and ex vivo tissue cultures 
study cells or organs in isolation from the myriad of other processes that are present 
in the body. While this is important for the simplification of early research, in vivo 
testing is important pre-clinical research that will have to be investigated before 
moving the treatment on to humans. For example, studies treating animals with NPs 
have shown that the NPs are likely to accumulate in the liver.163 This is an important 
consideration when deciding on the appropriate dose to balance therapeutic effect at 
the desired site with potential liver toxicity.  
Mouse lines can be bred to model some aspects of the disease symptoms of MS. 
Shiverer mice contain a mutation causing an absence of myelin basic protein, a major 
component of myelin sheaths, leading to a lack of compact myelin, and can be a 
useful tool in MS research.164 Experimental autoimmune encephalomyelitis (EAE) can 
be induced as an autoimmune T-cell driven mouse model of inflammation and 
demyelination in the central nervous system, which can model some of the early 
changes found in relapsing-remitting MS in humans, and Theiler’s murine 
encephalomyelitis virus also causes demyelination.165 Experimental demyelination 
can also be caused by treatment of mice with the toxin cuprizone,166 which gives 
global demyelination, or injection such as lysophosphatidyl choline (LPC) toxin into 
the brain or spinal cord to produce focal areas of demyelination.167 The choice of these 
models depends on the biological question to be answered. For example, the EAE 
model has been used successfully to test therapeutics working against T-cell driven 
inflammation,168 which have translated to humans. However, this would be an 
inappropriate model for testing therapeutics for enhancing remyelination, which might 
be better tested in a toxin-induced model where there is a well-described time course 
of demyelination and remyelination.  
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4.2 Cell Viability Assay 
The toxicity of the NPs in microglia was first assessed using the CellTiter-Glo 
luminescent viability assay (Promega). PLGA is an FDA approved polymer with a long 
and proven safety record,169 so it was important to compare the toxicity of the new 
bioorthogonal polymers (PLGA-D 23 and PLGA-alkyne 25) to PLGA NPs. NPs were 
formed using the emulsification-evaporation method and analysed with NTA to find 
particle size and concentration. The NPs were added to microglia in culture at 1, 2, 
and 4 × 109 particles mL-1. After a 24 hour incubation, the enzyme luciferase was 
added to the microglia, which reacts with adenosine tri-phosphate (ATP) and causes 
luminescence.170 Higher luminescence is attributed to a higher number of 
metabolically active cells. The luminescence of NP treated cells was compared to 
untreated, control cells that had been cultured for the same amount of time (Figure 
4.1). The mean luminescence of the control cells was set to 100%, and was used to 
scale the mean luminescence of the NP treatment conditions.  
 
 
Figure 4.1 Toxicity of the NPs to microglia in culture. PLGA, PLGA-D and PLGA-alkyne NPs 
were added to microglia at 1, 2, and 4 × 109 particles mL-1 and after a 24 h incubation, viability 
was assessed with the CellTiter-Glo luminescence assay. The luminescence of the untreated 
cells was set to 100%. The values for three biological replicates, with three wells per condition, 
were pooled and averaged. Error bars show standard error of the mean.  
Figure 4.1 shows that all of the NP concentrations tested were non-toxic, retaining 80% 
or more viability. Interestingly, most of the NP conditions, aside from PLGA NPs at 4 
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× 109 mL-1, had higher cell viability than the control cells. This could mean that the 
NPs have metabolically activated the cells, leading to more ATP production. A 
limitation of using the luminescence viability assay as opposed to directly counting 
single live and dead cells, is that the amount of live cells is only correlated to 
luminescence. However, the assay clearly shows that all the NPs tested were non-
toxic to microglia. 
 
4.3 Cell Pellet Raman Assay 
Initial experiments involved incubating PLGA-D and PLGA-alkyne NPs with a 
monolayer of microglia for 24 hours, then washing, pelleting and lyophilising these 
cells to give a solid cell pellet (Figure 4.2 A). The wash step served to remove any 
NPs that were not associated with the microglia.  
Figure 4.2 B shows analysis of the microglia treated with NPs by spontaneous Raman 
spectroscopy. The red, lower spectrum shows the Raman signal obtained from the 
cell pellet treated with PLGA-D NPs. This shows characteristic cellular peaks of CH3 
at 2939 cm-1, and CH2 at 2856 cm-1 that have been associated with proteins and lipids 
respectively,171 and a small, sharp peak at 1004 cm-1 in the fingerprint region which is 
caused by the aromatic group in the amino acid phenylalanine. However, there were 
no carbon–deuterium peaks present in the cell-silent region between 1800 and 
2800 cm-1. This could be because the NPs were not entering the microglia, or because 
the carbon–deuterium signal was not strong enough to be observed. 
 




Figure 4.2 Schematic of the cell pellet experiments and characteristic Raman spectra. A) 
Microglia were plated on day zero and were incubated overnight to allow them to adhere to 
the dish. The next day, NPs (PLGA-D or PLGA-alkyne) were resuspended in mixed glia media 
and added to the NPs. After a 24 h incubation, the microglia were washed, trypsinised, and 
then pelleted by centrifugation. The cell pellet was lyophilised to give a solid. Image created 
with Biorender.com. B) Spontaneous Raman spectroscopy of microglia plus PLGA-D NPs (red) 
and PLGA-alkyne NPs (blue), λex = 785 nm. 
In contrast, the microglia incubated with PLGA-alkyne NPs (blue spectrum) shows the 
characteristic cellular signatures, and also the bioorthogonal alkyne peak at 2128 cm-1. 
This indicates that the PLGA-alkyne NPs are entering the cells at a concentration high 
enough to be detected by spontaneous Raman, and that they are a good candidate 
for SRS imaging studies.  
 
Raman Imaging of Bioorthogonal Nanoparticles 
81 
 
4.4 Imaging Nanoparticles in vitro with SRS Microscopy 
4.4.1 Imaging in microglia 
Microglia were incubated with PLGA-D and PLGA-alkyne NPs and imaged with SRS 
microscopy to investigate their intracellular localisation. Again, the microglia were 
plated on day zero and were left overnight to adhere to the dish before the addition of 
PLGA-D or PLGA-alkyne NPs at 0.5, 1 and 2 × 109 particles mL-1. After a 24 h 
incubation with the NPs, the microglia were washed to remove free NPs, and then 
fixed. 
The fixed cells were then imaged with a custom-built SRS microscope (Figure 4.3), 
which consists of a tuneable pump laser and a spatially and temporally overlapped 
Stokes laser. The energy difference between the pump and Stokes lasers was tuned 
to match a molecular vibration of interest and thus create an image of this vibration.  
 
Figure 4.3 A schematic of the custom-built SRS microscope at The University of Edinburgh. 
An APE picoEMERALD laser system (A) provides two spatially and temporally overlapped 
beams. These are aligned through a series of focusing mirrors (B) to a beam expander (C) 
and then an FV1000 confocal scanning microscope (D). Image created by Dr Martin Lee. 
When imaging the NP resonance (2253 cm-1 for PLGA-D NPs and 2128 cm-1 for 
PLGA-alkyne NPs), an off-resonance image ~30 cm-1 away from the top of the on-
resonance peak was also acquired. This off-resonance image was always subtracted 
from the NP on-resonance image using Fiji,172 to ensure that the on-resonance signal 
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was derived from the NPs. Figure 4.4 shows an example of this process in images of 
microglia treated with PLGA-alkyne NPs.  
 
Figure 4.4 Image analysis of SRS images showing microglia treated with PLGA-alkyne NPs. 
Images were acquired at 2128 cm-1 (on-resonance) and 2095 cm-1 (off-resonance). 
Subtraction of the off-resonance signal from the on-resonance gave an image showing signal 
derived from the NPs only. Brightness and contrast settings are consistent throughout all 
images. Scale bars = 20 µm. 
To prove further that the signal in the images was derived from the bioorthogonal 
peaks on the NPs, SRS images were taken over a ~100 wavenumber interval, centred 
on the bioorthogonal peak derived from spontaneous Raman. This creates a 
hyperspectral image, where a range of spectral data for each pixel is captured. This 
shows that image intensity depends on a narrow spectral component that is most 
likely a vibrational response rather than another competing process, which are usually 
broader. For example, the PLGA-D has a peak at ~2253 cm-1 in its spontaneous 
Raman spectrum, so 21 SRS images were obtained between 2200 and 2311 cm-1. 
An area of NP intensity in the images was highlighted, and the intensity of this area 
was plotted over the stated wavenumbers using Fiji.  
Figure 4.5 A shows a comparison of the C-D peak obtained from the SRS images (red 
dots) and the spontaneous Raman spectroscopy (black line). This shows a good 
agreement between the SRS and spontaneous peaks. This process was repeated for 
the PLGA-alkyne peak, which also showed good agreement to its corresponding 
spontaneous Raman peak (Figure 4.5 B).  




Figure 4.5 Comparison of bioorthogonal peaks obtained from spontaneous Raman and SRS. 
A) The C-D peak at 2253 cm-1 analysed by spontaneous Raman (black line) and SRS (red 
squares). B) The C≡C peak at 2128 cm-1 analysed by spontaneous Raman (black line) and 
SRS (blue squares). 
Figure 4.6 shows the images obtained from microglia incubated with PLGA-D NPs. 
Tuning the energy difference between the lasers to 2939 cm-1 excites CH3 bonds 
which are indicative of cellular proteins. Similarly, tuning to 2856 cm-1 excites CH2 
bonds which highlights the lipid-rich cell membranes, and are notably absent from the 
nuclei. Although the cell pellet experiment with PLGA-D NPs was inconclusive as to 
whether the NPs had entered the microglia or not, Figure 4.6 shows that the NPs had 
been internalised. Tuning to one of the bioorthogonal carbon-deuterium peaks at 
2253 cm-1 allows the NPs to be visualised free of competing cellular vibrational 
components, although background still arises from competing refractive and thermal 
effects which are observed in the off-resonance images.173 The NPs were observed 
at all of the concentrations tested, and in the images in Figure 4.6, the off-resonance 
background has been subtracted from the carbon-deuterium signal at 2253 cm-1.  




Figure 4.6 PLGA-D NPs visualised in microglia by SRS microscopy. PLGA-D NPs were added 
to microglia at 0.5, 1 and 2 × 109 particles mL-1, and after a 24 h incubation the microglia were 
washed twice to remove free NPs and then fixed with 4% formaldehyde. The fixed cells were 
imaged by SRS microscopy. Brightness and contrast settings are inconsistent across these 
images to enhance contrast. Scale bars = 20 µm.  
This experiment was repeated with PLGA-alkyne NPs at 0.5, 1 and 2 × 109 
particles mL-1. The protein (2939 cm-1), lipid (2856 cm-1) and alkyne (2128cm-1) 
stretches were excited, with these images shown in Figure 4.7. Again, the NPs were 
visible at all concentrations and the alkyne images in Figure 4.7 are a product of the 
alkyne signal at 2128 cm-1 minus the off-resonance background. Over many biological 
replicates imaging both NPs with microglia, it became clear that the PLGA-alkyne NPs 
gave a stronger Raman signal and were observed more homogeneously throughout 
the cells, which is consistent with the spontaneous Raman results. Because of this, 
further experiments were carried out with the PLGA-alkyne NPs only. 




Figure 4.7 PLGA-alkyne NPs visualised in microglia by SRS microscopy. PLGA-alkyne NPs 
were added to microglia at 0.5, 1 and 2 × 109 particles mL-1, and after a 24 h incubation the 
microglia were washed twice to remove free NPs and then fixed with 4% formaldehyde. The 
fixed cells were imaged by SRS microscopy. Brightness and contrast settings are inconsistent 
across these images to enhance contrast. Scale bars = 20 µm. 
4.4.2 3D nanoparticle localisation 
The automated scanning of the lateral optical directions (X and Y) together with the 
optical axis (Z direction) allows confocal microscopy to construct 3D images of cells. 
SRS is also capable creating 3D cell images.174 Microglia treated with PLGA-alkyne 
NPs were imaged in this way to investigate the intracellular localisation of the NPs. 
Figure 4.8 shows these microglia in red, together with the orthogonal XZ and YZ 
planes, giving a 3D representation of the cell. The PLGA-alkyne NPs are represented 
in green, and when both the cellular and NP signals are overlaid, they appear yellow. 
The orthogonal views show that these yellow areas are within the cell body, confirming 
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that the NPs have been taken up into the microglia rather than just associated with 
the cell surface.  
 
Figure 4.8 Z-stack representation of PLGA-alkyne NPs in microglia. Microglia are shown in 
red and NPs in green, which overlay to give yellow. The orthogonal views in the XZ and YZ 
planes show that the NPs are internalised inside the microglia.  
4.4.3 Time dependent analysis of microglia 
The uptake of PLGA-alkyne NPs to microglia was investigated by fixing and imaging 
cells at different time points. Different dishes of microglia were fixed before addition 
of the NPs (t = 0), and then at 12, 24, 36, and 48 hours after addition. Two biological 
replicates were carried out from populations of primary rat microglia isolated from 
different litters of rat pups. For each biological replicate, three fields of view were 
imaged for each time point.  
For each image, quantification was carried out using Fiji to find the average alkyne 
intensity per cell. Firstly, the off-resonance image was subtracted from both the 
protein and alkyne on-resonance images (Figure 4.4). A threshold was then applied 
to the protein image to create a mask of the cells (Figure 4.9 A) which was made 
binary (Figure 4.9 B). A limitation of this threshold is that thin protrusions from the 
microglia were lost, but NPs were mainly observed in the cell body and not in these 
protrusions. The alkyne intensity within this cell mask could then be measured. Only 
areas above 50.26 µm2 (equivalent circular diameter of 8 µm) were analysed to 
exclude anything too small to be a cell, and to segment the mask into individual cells 
(Figure 4.9 C). This provided a list of the mean alkyne intensity per cell for each field 
of view. 




Figure 4.9 Quantitative analysis of alkyne intensity within a cell mask using Fiji. A) A threshold 
was applied to the cellular protein image to create a mask of the cell. B) This mask was then 
made binary. C) The alkyne intensity was measured within this mask in areas above 50.26 µm2.  
The intensity of alkyne measured between the two biological replicates showed high 
variation. For the first replicate, the maximum intensity was ~200 arbitrary units and 
for the second replicate, this increased to ~3000 arbitrary units. The microglia used in 
the two replicates were isolated from different litters of rat pups which could lead to 
differences, and primary cells are also heterogeneous in population.175 Microglia are 
also known to have varied states of activation in response to injury or trauma,176,177 
which will affect the amount of phagocytosis they carry out, and in turn, the amount of 
alkyne intensity observed within the cells. The intensity of SRS data can also change 
from day to day due to the gain functions and alignment of the microscope. These 
sources of variability mean that it is possible to draw comparisons between individual 
time points in a biological replicate, as these come from the same batch of primary 
cells and were imaged on the same day, but it is difficult to compare between 
biological replicates which is why the data were not pooled.  
Figure 4.10 A and B show representative images of the cells at each time point from 
biological replicates one and two respectively. Both show that there is no alkyne 
intensity at time zero before NP addition, and that NPs are visible from 12 hours. The 
mean alkyne intensity per cell was plotted as a box plot over time for each replicate. 
In replicate one (Figure 4.10 C), alkyne intensity increases up until 24 hours, and then 
begins to decrease until 48 hours where the alkyne intensity is not significantly 
different to before the addition. In replicate two (Figure 4.10 D) the alkyne intensity 
continues to increase until 48 hours.  




Figure 4.10 Time course analysis of the uptake of PLGA-alkyne NPs into microglia. Microglia 
were treated with PLGA-alkyne NPs at 2 × 109 particles mL-1, and at 0, 12, 24, 36 and 48 hours 
after the NP addition, the cells were fixed and imaged with SRS. A and B show representative 
images from replicate one and two respectively. Brightness and contrast settings are 
consistent throughout all images. Scale bars = 20 µm. C and D show image quantification for 
replicated one and two respectively. For each time point, the alkyne intensity was quantified 
for individual cells over three fields of view with n giving the number of cells quantified per 
condition. ***: p < 0.001; n.s.: p > 0.05, Mann-Whitney U test. 
In replicate two (Figure 4.10 D), the number of cells counted decreases from ~200 at 
time zero to ~60 at the other time points. This suggests that cells may have been 
dying, although this concentration of PLGA-alkyne NPs was shown to be non-toxic in 
Figure 4.1.  
4.4.4 Imaging PLGA-alkyne NPs loaded with rhodamine 
To investigate if the bioorthogonal PLGA-alkyne NPs were capable of encapsulating 
and delivering drugs to microglia, the NPs were loaded with rhodamine, which is a 
red-fluorescent dye (λex 528 nm, λem 553 nm), as a model payload. The rhodamine 
loaded NPs were prepared using the standard emulsification-evaporation method with 
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the addition of rhodamine to the organic phase. The alkyne signal from the NPs and 
the fluorescent signal from rhodamine allowed a multimodal imaging platform to be 
used to study the localisation of the NPs and their payload in microglia (Figure 4.11). 
 
Figure 4.11 Multimodal imaging of PLGA-alkyne NPs loaded with rhodamine. Microglia were 
incubated with PLGA-alkyne NPs encapsulating the fluorescent dye rhodamine at 2 × 109 
particles mL-1 for 24 hours before washing and fixing the cells. They were then imaged with 
both SRS and two-photon fluorescence microscopies, which showed that the alkyne signal of 
the NPs (green, 2128 cm-1) co-localises with the fluorescent signal of rhodamine (red; λex 528 
nm, λem 553 nm). Scale bars = 20 µm.  
Figure 4.11 shows SRS and two-photon fluorescence (TPF) imaging of microglia 
incubated with rhodamine loaded PLGA-alkyne NPs. Tuning to 2128 cm-1 with SRS 
shows the location of the NPs (green), and the red fluorescence channel allowed 
visualisation of rhodamine (red). Overlaying these two images showed that the 
rhodamine and alkyne signals co-localise well (yellow), which indicates that the 
rhodamine is encapsulated inside the NP and shows the potential of these NPs to be 
used for both imaging and drug delivery.  
   
4.5 Imaging Nanoparticles ex vivo with SRS Microscopy 
The PLGA-alkyne NPs were then imaged in ex vivo cortical mouse brain slices. These 
slices were isolated from postnatal mice pups and were cultured on inserts for six 
days before the addition of NPs. These six days were allowed to elapse because there 
can be significant cell death when slices are first cultured due to the cutting process. 
NPs were added to the slices at 2 × 108, 2 × 109 and 2 × 1010 particles mL-1 followed 
by a 24 hour incubation period (Figure 4.12 A).  




Figure 4.12 Imaging PLGA-alkyne NPs in ex vivo mouse brain slices. A) Brains were isolated 
and sliced from P5 mice pups and were cultured for 6 days before the addition of PLGA-alkyne 
NPs at 2 × 108, 2 × 109 and 2 × 1010 particles mL-1. After 24 hours of incubation, the slices 
were washed and fixed. Image created with Biorender.com. B) Representative images of the 
slices treated with 2 × 1010 particles mL-1, showing proteins in grey (2939 cm-1) and PLGA-
alkyne NPs in magenta (2128 cm-1). Scale bars = 20 µm.  
Figure 4.12 B shows the SRS images obtained from brain slices treated with PLGA-
alkyne NPs at 2 × 1010 particles mL-1. Tuning to the protein stretch at 2939 cm-1 shows 
the morphology of the tissue, and tuning to the alkyne frequency at 2128 cm-1 shows 
that there are NPs visible on the slice. The image analysis of the brain tissue is much 
more complex than the microglia cultures due to overlapping protein signals from the 
different types of cells and extracellular proteins. It was therefore not possible to 
determine what kind of cell the NPs were inside using these images. 
4.5.1 Immunohistochemical analysis 
To determine if the NPs in the brain slice had been internalised within cells, and what 
type of cells these were, immunohistochemical analysis was carried out on the tissue. 
Immunohistochemistry allows the fluorescent imaging of specific proteins by binding 
antibodies to them. A primary antibody specific to the protein of interest is first 
incubated with the tissue, followed by incubation with a secondary fluorescent 
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antibody, which will bind to the primary antibody. In this way, multiple proteins can be 
visualised in the same tissue using different fluorescent dyes. 
In the brain slices, microglia were stained red using antibodies against IBA1, a 
microglial specific protein,178 and oligodendroglia were stained green using antibodies 
against OLIG2, an oligodendroglial specific nuclear protein. Fluorescence images 
could also be obtained on the SRS set-up, which allowed multimodal imaging on the 
same area of the brain slices to be carried out. Figure 4.13 shows representative 
images of the immunostained brain slices treated with PLGA-alkyne NPs at 2 × 108, 
2 × 109 and 2 × 1010 particles mL-1 with microglia in red, oligodendroglia in green and 
NPs in magenta. 
The NPs were visible at all concentrations tested, and the immunohistochemical 
staining showed that the NPs were associated with the microglia. Z-stack analysis of 
the tissue confirmed that the NPs had been internalised inside the microglia (Figure 
4.13 B), and there were no NPs observed within the oligodendroglia. This result was 
expected, as oligodendroglia are not usually phagocytes, and without additional 
targeting ligands, the NPs would not be expected to associate with them. However, 
this gives these NPs the potential for targeted drug delivery to microglia. 
 
Figure 4.13 Immunohistochemical analysis of ex vivo brain slices. A) SRS and TPF images 
showing microglia in red (IBA1, Alexa Fluor® 568 nm), oligodendroglia in green (OLIG2, Alexa 
Fluor® 488 nm) and PLGA-alkyne NPs in magenta. White arrows indicate the location of NPs 
inside the microglia. Scale bars = 20 µm. B) Orthogonal views (XZ and YZ) from Z-stack 
analysis show that the NPs have been internalised inside a microglia. Scale bar = 50 µm. 
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4.5.2 Time dependent analysis of brain slices 
An experiment was carried out to investigate the behaviour of NPs incubated with ex 
vivo brain slices over time. An advantage of carrying out this time dependent analysis 
on slices rather than microglia cultures is that the slices could be cultured for several 
weeks. In the microglia time course experiment (Section 4.4.4), the maximum time 
point imaged was 48 hours, but in this experiment, PLGA-alkyne NPs were added to 
the slices which were then fixed and imaged one, three and seven days after NP 
addition. For this experiment, microglia were again stained red using antibodies 
against IBA1, and the nucleic acid stain SYTO 9 (λex 485 nm, λem 498 nm) was used 
to stain all nuclei green, which allowed quantification of the cells.  
 
Figure 4.14 Time dependent analysis of PLGA-alkyne NPs in ex vivo brain slices. NPs were 
added at 1 × 1011 particles mL-1 and then the slices were fixed and imaged with SRS and TPF 
microscopies one, three and seven days after NP addition. Microglia were stained red using 
antibodies against IBA1 (Alexa Fluor® 568 nm), nuclei were stained green using SYTO 9 (λex 
485 nm, λem 498 nm) and the NPs are shown in cyan hot (SRS at 2128 cm-1). Three 
representative images are shown for each time point. Brightness and contrast setting for the 
NP signal (cyan) are consistent throughout. Scale bars = 20 µm. 
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Figure 4.14 shows three representative images from each time point tested. Again, 
multimodal imaging was carried out, with TPF showing microglia in red and nuclei in 
green, and SRS showing the location of the NPs in cyan. This shows that there were 
NPs visible at every time point, and that they were associated with the microglia. 
Two methods of quantification were used to determine the amount of NPs present in 
the tissue over time. The first method was to count the number of microglia that 
contained NPs at each time point. The images showed areas where there were large 
aggregates of microglia and NPs, making it impossible to count individual cells. For 
the purposes of this quantification, these areas were discounted, and only a sample 
of the image was counted. Examples of areas counted and discounted are shown in 
Figure 4.15 A and B respectively. The same overall area was quantified for each field 
of view. The total number of microglia were counted, with a microglia only counted if 
it had a visible nucleus, and then the number of microglia containing NPs was counted. 
This allowed the percentage of microglia containing NPs to be calculated for each 
time point. This showed that the percentage of microglia containing NPs increased 
from day one to three, and had decreased again by day seven (Figure 4.15 C). 
 
Figure 4.15 Counting the number of microglia containing NPs in ex vivo brain slices. A) 
Examples of areas containing well-separated microglia with clearly visible nuclei that were 
included in the quantification. Scale bars = 15 µm. B) Examples of areas containing 
aggregates of cells and NPs that were excluded from the quantification. Scale bars = 15 µm. 
C) Bar chart showing the percentage of microglia containing NPs over time where n = the total 
number of cells counted for each time point.  
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A disadvantage of this method is that only a sample of the slice could be quantified, 
and the clumps that contained most of the NP intensity had to be discounted. To 
overcome this, a second method was used to quantify the alkyne intensity within a 
microglial mask over the whole field of view using Fiji. A microglia threshold mask was 
created from the red fluorescence channel as described previously (Figure 4.9). There 
was some interaction between the SRS and fluorescence channels meaning that 
there was no fluorescence signal where there were NPs (Figure 4.16 A). When the 
mask was created, the fill holes function was used to fill in these gaps. Nine fields of 
view from two brain slice replicates were imaged for each time point, and the mean 
alkyne intensity was calculated for each field of view. This shows that the alkyne 
intensity significantly increases between one and three days, and then decreases 
back to day one levels after seven days (Figure 4.16 B).  
 
Figure 4.16 Quantifying alkyne intensity over time in ex vivo brain slices. A) Images showing 
microglia in red and PLGA-alkyne NPs in cyan hot. Where there are NPs present, there is an 
absence of fluorescent signal. Scale bars = 15 µm. B) Box plot showing the mean alkyne 
intensity per field of view over time. Each dot represents one field of view. ***: p < 0.001; **: p 
< 0.01; n.s.: p > 0.05, Mann-Whitney U test. 
Both methods of quantification show that the intensity of NPs increases between one 
and three days. This confirms what was observed in the microglia culture time course, 
where there was an induction period in the uptake of NPs. Microglia were counted as 
positive for containing NPs if there was any visible alkyne signal, so this does not take 
into account the size of the NP aggregate.  
The intensity of NPs inside the microglia significantly increased between one and 
three days. This could be because the microglia are internalising more NPs over time, 
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or because they are being packaged together in a larger structure, which will result in 
a higher alkyne intensity. NPs internalised by phagocytosis will be encapsulated in 
phagosomes inside the cell, and over time, these are likely to mature to lysosomes.179 
This could be confirmed by staining for lysosomes, which should correlate well with 
the areas of NPs. Lysosomal degradation of the NPs could also account for the 
significant decrease in alkyne intensity observed between three and seven days. 
 
4.6 Imaging Nanoparticles in vivo with SRS Microscopy 
After successfully imaging the PLGA-alkyne NPs in both primary microglia cultures 
and ex vivo mouse brain slices, the next step was to study the interaction of the NPs 
with the brain of a live organism. Two methods of delivery to live mice were 
investigated; direct injection into the brain and intranasal delivery (Figure 4.17).  
 
Figure 4.17 Methods of delivering NPs to the brain of live mice. A) 2 µL of PLGA-alkyne NPs 
at 4 × 1011 particles mL-1 were directly injected into the mouse brain by stereotactic surgery. 
At two or 24 hours after NP injection, the mice were perfused with formaldehyde, the brains 
removed and cut into 100 µm sections. Live animal work was carried out by Amanda Boyd. B) 
50 µL of PLGA-alkyne NPs at 1 × 1011 particles mL-1 were delivered to mice intranasally. 24 
hours after delivery, the mice were perfused with formaldehyde, the brains removed and cut 
into 100 µm sections. Live animal work was carried out by Dr Matthew Swire and Amanda 
Boyd. 
4.6.1 Direct injection to mouse brain 
PLGA-alkyne NPs were directly injected into the corpus callosum of a live mouse 
using stereotactic surgery. Stereotactic surgery is a technique where three-
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dimensional coordinates mapped from a dissected mouse brain are used to perform 
surgery at a specific location.180 To investigate the behaviour of the NPs in mice over 
time, groups of mice were sacrificed two and 24 hours after NP injection, the brains 
were removed, sectioned and imaged with SRS.  
The stereotactic surgery method meant that the injection coordinates were known, so 
the NPs were most likely to be found in this area, however, when tuning to the alkyne 
stretch at 2128 cm-1, no NPs were visible in the brain sections. Due to animal licence 
requirements, only 2 µL of NPs could be injected into the brain. It is possible that this 
concentration is too low to be visualised by SRS, or that the NPs became too 
dispersed throughout the brain to locate. Backflow of NPs after the injection needle 
was removed could also mean that the NPs failed to enter the brain, although the 
needle was held in place for four minutes after the injection to minimise the chance of 
backflow.  
4.6.2 Intranasal delivery 
Intranasal administration of drugs is emerging as an attractive method of delivery to 
the brain, as the BBB can be bypassed in this way via the olfactory and trigeminal 
pathways.181,182 This technique has been used previously to deliver therapeutics 
directly to the brain.183,184 Gambaryan et al. demonstrated how intranasal delivery of 
PLGA NPs loaded with the Parkinson’s disease drug L-DOPA (Mw = 197.2 Da, 
Appendix 2) gave a sustained therapeutic effect over free L-DOPA delivered 
intranasally.185 Additionally, PLGA NPs have been used to deliver the antipsychotic 
drug olanzapine (Mw = 314.5 Da, Appendix 2),186 antiepileptic peptide drugs,187 and 
another Parkinson’s disease drug rotigotine (Mw = 329.5 Da, Appendix 2), 
intranasally.188 
Adult mice were administered 50 µL of PLGA-alkyne NPs at 1 × 1011 particles mL-1 
intranasally, and after 24 hours, their brains were removed and imaged. Imaging 
focused on the sections containing the olfactory bulb, as this is the expected 
intranasal route, but no NPs were observed by SRS. Again, it is unclear whether this 
is because the NPs never entered the brain, they were too disperse, or the correct 
section had not been imaged. An automated high-throughput way of screening the 
brain sections for alkyne signal could assist in finding any NPs in future studies. It has 
been reported that intranasal drug delivery can be limited by low mucosal permeability 
and enzymatic degradation,189 although encapsulation of drugs into a biodegradable 
NP should help overcome these issues.  




In this chapter, the new, bioorthogonally labelled PLGA-D and PLGA-alkyne NPs 
were imaged with SRS microscopy in biological models of the brain. Both NPs were 
first imaged in primary microglia cultures, with the PLGA-alkyne NPs giving a stronger 
signal. For this reason, the subsequent studies were only carried out with PLGA-
alkyne NPs. Image analysis revealed that the NPs were internalised within microglia, 
and time course studies showed how the NPs were taken up over time, highlighting 
differences between batches of microglia. 
The PLGA-NPs were then imaged in ex vivo brain slices, where 
immunohistochemistry showed that the NPs were selectively taken up into microglia 
over oligodendorglia. This gives them potential for targeted drug delivery to microglia. 
Two delivery methods were then investigated in live mice; direct brain injection and 
intranasal, however, no NPs were visualised in the brains by SRS. It is not known if 
the NPs did not enter the brain, or if their low concentration or diffuse distribution did 






















Chapter 5 Future Work 
In this thesis, SRS microscopy was successfully used to image bioorthogonally 
Raman labelled polymer NPs in biological models of the brain. Nanoscience is a fast-
growing technology in the field of drug delivery, and has great potential for the delivery 
of therapeutics across the blood brain barrier.190 The ability to track NPs in vitro and 
in vivo is vital for conferring their function, lifetime and safety, and SRS microscopy 
provides an ideal platform to image NPs free of cellular background.  
In Chapter 1, previous strategies to image polymeric and liposomal NPs were 
discussed which included fluorescence, confocal Raman and coherent Raman 
microscopies. Small, spectroscopically bioorthogonal labels (C-D, C≡N and C≡C) 
which produce peaks in the cell silent region have also been shown to increase the 
contrast of NPs in cellular and tissue models.  
Chapter 2 discussed the synthetic route to two spectroscopically biorthogonal 
analogues of PLGA: PLGA-D and PLGA-alkyne. Deuterated lactic acid was used in a 
polycondensation reaction to synthesise PLGA-D, whilst PLGA-alkyne was formed 
via ROP from a cyclic propargyl DOX monomer. The same chemistry used to 
synthesise propargyl DOX could be applied to the deuterated lactic acid to form a 
cyclic monomer, and therefore a higher molecular weight polymer. However, this 
would not increase the Raman signal of the PLGA-D.  
Since alkyne peaks are generally small and sharp, multiple alkyne-containing tags 
can be imaged at once, as has been shown previously.191 This method could also be 
applied to PLGA, where multiple alkyne analogues are synthesised giving rise to a 
palette of NPs suitable for multi-colour Raman imaging. These NPs could be used to 
label different cell populations and track their fate when mixed, similar to previous 
studies with fluorescent NPs.62 
In Chapter 3, the synthesis of NPs with the emulsification-evaporation method was 
described. Several targeting strategies were then discussed to attempt to conjugate 
avidin to the surface of the NPs, however, none of these strategies produced avidin 
binding significantly higher than the control. An additional strategy for targeting PLGA 
NPs is to react proteins onto a carboxylic acid polymer end group, which is more easily 
functionalised than the alcohol end group that was present in PLGA-alkyne. Previous 




these conditions could be replicated to bind avidin. The carboxylic acid end group 
would first be activated to its NHS ester, which could then form an amide bond with a 
free amine on the avidin ( Scheme 5.1). Alternatively, this chemistry could be utilised 
to conjugate the NP directly to the targeting antibody. 
 
Scheme 5.1 Conjugation of avidin to a NP through an amide bond. EDC and NHS could be 
used to activate a carboxylic acid polymer end group to its NHS ester (i). Addition of avidin 
would then cause reaction of this NHS ester with a lysine residue, joining avidin to the NP 
through an amide bond.  
Once NG2 targeted PLGA-alkyne NPs were available, they could be used to deliver 
drugs to OPCs,20 and SRS microscopy could be used to image their intracellular 
localisation. Targeted NPs could also be incubated with a mixed culture of OPCs and 
microglia followed by immunostaining and multimodal SRS and TPF imaging to 
investigate if the NG2 targeting would mean they were preferentially internalised in 
OPCs, or still engulfed by microglia. This experiment could also be repeated in ex vivo 
brain slices, and would provide important information about the ability of these NPs to 
target OPCs.  
It was shown in Chapter 4 that PLGA-alkyne NPs were selectively internalised in 
microglia over oligodendrocytes in ex vivo brain slices, showing that they have a 
potential for targeted drug delivery to microglia. Future work could focus on loading 
therapeutics into the PLGA-alkyne NPs, which was shown to be possible by using 
rhodamine as a model payload, and delivering them to microglia.  
Preliminary experiments were carried out in collaboration with Dr Dirk Seiger, who 
studies the role of microglia in glioblastoma using zebrafish models. In these models, 
it has been shown that microglia will migrate to a tumour and, instead of performing a 
protective phagocytic role as expected, will initiate tumour growth.193 Understanding 
this mechanism of action, and finding drugs to reverse it, is important research in 
efforts to treat glioblastoma. PLGA-alkyne NPs could be used to deliver drugs to 
microglia in these models, and image their location with SRS. Initial experiments 
confirmed that the NPs were non-toxic to zebrafish, and zebrafish were imaged with 
SRS microscopy after a 24 hour incubation with PLGA-alkyne NPs in their water 




suitable for the imaging of zebrafish, and future studies injecting NPs into the brain 
could allow both imaging and drug delivery.  
 
Figure 5.1 Imaging zebrafish with SRS microscopy. Tuning to the protein stretch at 2939 cm-1 
allows imaging of the zebrafish. Scale bar = 500 µm. 
In Chapter 4, in vivo studies were described where PLGA-alkyne NPs were either 
injected into the mouse brain, or delivered intranasally, before sacrificing the mice and 
imaging sections of the fixed brain. In both of these experiments, the alkyne signal of 
the NPs could not be found. In future experiments, PLGA-alkyne NPs loaded with a 
fluorescent dye could be administered as the fluorescent signal would be brighter than 
the SRS alkyne signal, and it would be quicker to sort through the sections to find the 
NP location, however, neurons in brains are often autofluorescent which may make it 
difficult to detect NPs. Furthermore, delivery of a higher concentration of NPs may 
help be certain of their detection after in vivo delivery. Emerging technology has also 
shown that live mice can be fitted with transparent cranial windows to allow brain 
imaging in a live animal.194,195 The combination of this technology with the PLGA-
alkyne NPs could be used to track the NPs live in a mouse brain with SRS microscopy. 
Although NP drug delivery is popular in pre-clinical studies, translation to humans is 
still limited by concerns about long-term distribution, safety and degradation.196 
Imaging NPs is therefore an important technique for answering these questions. Other 
issues such as relatively low drug loading and targeting efficiency also need to be 
overcome.197 NPs will naturally accumulate in macrophages,198 the liver,199 and 
tumours,200 and therefore drug delivery to these targets could be more easily realised 
along with NP imaging. Medina et al. recently developed PLGA NPs quantum dot 
conjugates to study the in vivo fate of the NPs, and if they passed the BBB.201 They 




when there was a tumour this disrupted the BBB and allowed the NPs to enter. At a 
higher concentration, the PLGA-alkyne NPs could be used to visualise if and how 
these NPs cross the BBB, providing important information about the potential of PLGA 
NPs to deliver drugs to the brain.     
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Chapter 6 Materials and Methods 
6.1 General Procedures 
6.1.1 Chemical synthesis 
All non-aqueous reactions were carried out in oven-dried glassware which was 
assembled hot and then allowed to cool under a dry nitrogen atmosphere. Unless 
otherwise stated, all starting materials and reagents were used as received from the 
supplier. Dry solvents were dried via a solvent purification system (SPS) using 
activated alumina. Saturated aqueous solutions of inorganic salts are represented as 
(volume, sat. aq.). 
1H and 13C NMR spectra were obtained on Brucker instruments at the stated 
frequency using TMS as a reference and residual solvent as an internal standard. 
Infrared spectra were recorded neat on a Shimadzu IRAffinity-1 with a diamond optic. 
Gel permeation chromatography was carried out in THF at a flow rate of 1 mL min−1 
at 35°C on a Viscotek 270 GPC Max triple detection system (Malvern Instruments) 
with 2 × mixed bed styrene/DVB columns (300 × 7.5 mm). Data was processed using 
OmniSEC 5.0 using either the triple detection or conventional calibration method and 
calibrating with polystyrene standards. Mass spectra were obtained on a MAT 900 XP 
mass spectrometer (electron ionisation). Melting points were determined on a 
Gallenkamp Electrothermal Melting Point apparatus and are uncorrected. Reverse 
phase UPLC was performed on a Waters Acquity system using a binary solvent 
manager and PDA equipped with a Waters BEH C4, 1.7 µm, 100 × 2.1 mm column 
using water (0.1% TFA) and acetonitrile as an eluent at a flow rate of 0.2 mL min-1. Rf 
values were obtained on Merck Silicagel 60 aluminium backed plates. Flash column 
chromatography was carried out using Geduran ® Si 60 silica (40–60 µm) (Merck 
Millipore) under positive pressure. Eluent compositions are stated as volume/volume 
ratios. 
6.1.2 Nanoparticle synthesis 
Nanoparticle emulsions were formed using a probe tip sonicator (Soniprep 150, MSE). 
Nanoparticles were pelleted by centrifugation on a VWR Microstar 17 centrifuge. For 
TEM analysis, NP suspensions in water were dropped onto TEM grids and then 
allowed to dry at room temperature. TEM images were obtained on a JEOL JEM-1400 
Plus TEM. Representative images were collected on a GATAN OneView camera. For 
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SEM analysis, NP suspensions in water were mounted on aluminium stubs with 
carbon tabs attached and dried under vacuum, before the specimens were sputter 
coated with 20 nm gold palladium and viewed using a Hitachi S-4700 scanning 
electron microscope. Brightfield images were acquired with a Nikon Eclipse TE 2000-
U inverted microscope at 20–22°C using a 20 × (CFI Fluor, N.A. 0.5, Nikon) objective 
and recorded with an EMCCD (iXon Ultra 897, Andor Technology) at -50°C. Dynamic 
light scattering was carried out on a Zetasizer Nano ZS (Malvern Panalytical) in water 
at 25°C. Nanoparticle tracking analysis was carried out on a Nanosight LM10 (Malvern 
Panalytical) in PBS with the temperature measured for each individual run. UV 
analysis was obtained on a Varian Cary ® UV-vis Spectrophotometer, Agilent. 
Lyophilisation was achieved by freezing samples in liquid nitrogen and then freeze 
drying on a Lablyo mini (Frozen in Time Ltd) freeze drier. NPs were resuspended in 
the appropriate media and warmed to 37°C before addition to microglia and brain 
slices. 
Table 6.1 Preparation of standard solutions for NP reactions. 
Solution Preparation 
Aqueous phase for NP 
synthesis 
100 mg Poly(vinyl) alcohol, (Mw 31,000–50,000, 98–
99% hydrolysed) 
20 mg Sodium dodecyl sulphate 
10 mL dH2O 
1 M HEPES, pH 8 119.15 g HEPES 
500 mL dH2O, adjusted to pH 8 with NaOH (3 M, aq.) 
Sodium deoxycholate 
solution 
20 mg Sodium deoxycholate solution 
10 mL 1 M HEPES 
 
6.1.3 Tissue culture 
Cells were counted by taking 9 µL of cell suspension into a haemocytometer and 
averaging the cell count obtained from four 1 mm2 grids. All media and reagents were 
warmed to 37°C before addition to cells/slices. Cell fixation was achieved by covering 
the cells with a solution of 4% formaldehyde (2 mL) for 10 minutes at room 
temperature before washing three times with PBS (3 × 2 mL). Unless otherwise stated, 
PBS refers to 1 × PBS at pH 7.4. The plate reader used for viability assays was a 
GloMax Microplate Reader (Promega). 
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Table 6.2: Preparation of standard solutions for tissue culture. 
Solution Preparation 
1 × PBS 100 mL 10 × PBS pH 7.4 (Gibco) 
900 mL dH2O 
Fixing solution 1 mL 37% Formaldehyde (Sigma Aldrich) 
9 mL 1 × PBS 
Mixed glia media 1 L Dulbecco’s modified Eagle’s medium (Gibco) 
100 mL Fetal calf serum 
1 mL Penicillin-streptomycin 
Slice media 25 mL Minimal essential media (Invitrogen) 
12.5 mL Heat-inactivated horse serum (Invitrogen) 
12.5 mL Earle’s balanced salt solution (Invitrogen) 
500 µL Glutamax supplement (Invitrogen) 
500 µL Penicillin-streptomycin 
250 µL Fungizone (Invitrogen) 
722 µL 45% Glucose (Sigma Aldrich) 
Blocking solution (for 
immunostaining) 
1.5 mL Heat-inactivated horse serum 
1 g Bovine serum albumin 
2.5 mL Triton (10%, (v/v) aq.) 
45 mL 1 × PBS 
 
6.1.4 Spontaneous Raman 
Spontaneous Raman spectra were acquired on a confocal Raman spectrometer 
(inVia Raman microscope, Renishaw). A 297 mW (206 mW after objective) 785 nm 
diode laser or a 200 mW 532 nm laser excitation source was used to excite the sample 
through a 20× or 50× objective. The instrument was calibrated using a silicon wafer 
before each use so that the silicon peak was 520.5 cm-1. All spectra were background 
subtracted using the background correction algorithm available on the Wire 4.4 
software.  
Since glass has a high Raman background, all spectra were acquired on CaF2 slides. 
The slides were washed in ethanol (70%, aq.) between samples and reused.  
6.1.5 Stimulated Raman scattering 
Images were acquired using a custom-built multi-modal microscope. A picoEmerald 
(APE, Berlin, Germany) laser gave a tuneable pump laser (720–990 nm, 7 ps, 80 MHz 
repetition rate) and a spatially and temporally overlapped Stokes laser (1064 nm, 5–
6 ps, 80 MHz repetition rate). Back scattered RFP two-photon fluorescence signals 
were filtered using the following series of filters: FF552-Di02, FF440/520-Di01 
(Semrock) and HQ610/75m (Chroma). For SRS measurements, the Stokes beam 
was modulated with a 20 MHz EoM. Forward scattered light was collected by a 20× 
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Olympus XLUMPLFLN Objective, 1.00 NA lens and filtered using ET890/220m filter 
(Chroma). A telescope focused the light onto an APE silicon photodiode connected to 
an APE lock-in amplifier which was fed into the analogue unit of the microscope. 
The pump laser was tuned to 810.5 nm (2930 cm-1), 816 nm (2850 cm-1), 867.5 nm 
(2128 cm-1) and 858.3 nm (2252 cm-1) and laser powers after the objective were 
measured up to 40-70 mW for the pump laser and up to 70 mW for the Stokes laser. 
All images were recorded at 512 × 512 or 1024 × 1024 pixels with a pixel dwell time 
between 2 and 20 μs by FV10-ASW software (Olympus). 
All cells were grown on FluoroDish Cell Culture Dishes (World Precision Instruments) 
which have an optical glass bottom for high quality imaging. Since SRS focuses on a 
specific wavenumber, the background signal from glass is not an issue. New dishes 
were used for each experiment. A sweep of SRS images was obtained to check if the 
SRS peak matched the wavenumber of the spontaneous peak as a form of calibration. 
6.1.6 Image analysis 
All images were processed using Fiji (ImageJ) software172 by assigning false colour 
assignments and scale bars. When acquiring SRS images, an off-resonance image 
was always acquired ~30 cm-1 away from the target resonance. When processing the 
images, this off-resonance was subtracted from the on-resonance using the image 
calculator functionality on ImageJ.  
 
6.2 Experimental Procedures for Chapter 2 
6.2.1 Synthesis of lactic acid-d3 
2-(tert-Butoxy)acetic acid 11 
Potassium tert-butoxide 10 (32.0 g, 283 mmol) was dissolved in 
anhydrous THF (~100 mL). Bromoacetic acid 9 (15.8 g, 113 mmol) 
was dissolved in THF (10 mL) and added dropwise to the potassium tert-butoxide 
solution with stirring. Upon addition, a pale yellow solid precipitated. The reaction 
mixture was heated to reflux and stirred for one hour. The THF was removed in vacuo 
and ether (~50 mL) was added to the residue. Hydrochloric acid (~50 mL, 3M, aq.) 
was added until all of the solid had dissolved, and the aqueous phase was acidic. The 
aqueous phase was extracted twice with ether (2 × 50 mL) and then the combined 
organic layers were washed with brine (~50 mL sat. aq.), dried (MgSO4) and the ether 
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removed in vacuo to give the desired product 11 as a yellow oil (13.6 g, 103 mmol, 
91%). Rf (DCM:MeOH 4:1) = 0.52; IR (neat cm-1) 2976, 2937 (C-H), 1732 (C=O); 1H 
NMR δ (400 MHz, CDCl3) 4.02 (2H, s, CH2), 1.26 (9H, s, (CH3)3); 13C NMR δ (126 
MHz, CDCl3) 173.2 (C), 75.8 (C) 60.1 (CH2) 27.4 (3 × CH3). The spectroscopic data 
are in good agreement with the literature.202  
 
Benzyl 2-(tert-butoxy)acetate 13 
2-(tert-Butoxy)acetic acid 11 (9.00 g, 68.0 mmol), 4-
(dimethylamino)pyridine (0.830 g, 6.80 mmol) and 
phenylmethanol (14.1 mL, 136 mmol) were dissolved in anhydrous DCM (150 mL). 1-
Ethyl-3(3-dimethylaminopropyl)carbodiimide (14.3 g, 74.8 mmol) was added portion-
wise and the mixture was left stirring at room temperature under argon for ~18 hours 
until the reaction was confirmed to be complete by TLC. The mixture was washed with 
hydrochloric acid (~100 mL, 0.5 M, aq.), brine (~100 mL, sat. aq.) and NaHCO3 (~100 
mL sat. aq.). The organic layer was dried (MgSO4) and the DCM removed in vacuo to 
give a yellow oil. The oil was further purified by flash column chromatography 
(Hexane:EtOAc 9:1) to give the desired product 13 as a colourless oil (12.5 g, 56.0 
mmol, 82%). Rf (Hexane:EtOAc 9:1) = 0.20; IR (neat cm-1) 2974 (C-H), 1759 (C=O), 
1456 (ArC=C); 1H NMR δ (600 MHz, CDCl3) 7.37-7.30 (5H, m, ArH), 5.17 (2H, s, CH2), 
4.06 (2H, s, CH2), 1.22 (9H, s, (CH3)3); 13C NMR δ (151 MHz, CDCl3) 171.2 (C), 135.7 
(C), 128.6 (2 × ArCH), 128.4 (2 × ArCH), 128.4 (ArCH), 74.6 (C), 66.5 (CH2), 60.9 
(CH2), 27.3 (3 × CH3); m/z (EI), 222.1 ([M+˙], 1.3%), 166.1 (100), 107.0 (36.6); HRMS 
(EI) [M+˙] found 222.1257, C13H18O3 requires 222.1251. 
 
Benzyl 2-(tert-butoxy)propanoate 15 
Benzyl 2-(tert-butoxy)acetate 13 (0.500 g, 2.25 mmol) was 
dissolved in anhydrous THF (10 mL) under argon and 
cooled to -78°C before adding LiHMDS (5.63 mL, 5.63 mmol, 1 M in THF) dropwise. 
The mixture was stirred at -78°C for 1 hour before adding iodomethane (0.280 mL, 
4.50 mmol) that had previously been filtered through anhydrous potassium carbonate. 
The mixture was then allowed to warm to room temperature over 30 minutes. The 
reaction was confirmed to be complete by TLC, and hydrochloric acid (~25 mL, 0.5 
M, aq.) was added until the reaction mixture was acidic. The THF was removed in 
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vacuo and ether (~20 mL) was added to the mixture. The organic layer was separated, 
and the aqueous layer was extracted with ether (3 × 10 mL). The combined organic 
layers were washed with brine (~10 mL, sat. aq.) and NaHCO3 (~10 mL, sat. aq.) 
before drying (MgSO4). The ether was removed in vacuo to give a yellow oil which 
was further purified by flash column chromatography (Hexane:EtOAc 9.5:0.5) to give 
the desired product 15 as a colourless oil (0.170 g, 0.710 mmol, 32%). Rf 
(Hexane:EtOAc 9.5:0.5) = 0.24; IR (neat cm-1) 2976 (C-H), 1753 (C=O), 1456 (ArC=C); 
1H NMR δ (600 MHz, CDCl3) 7.37-7.20 (5H, m, ArH), 5.18 (1H, d, J = 12.3 Hz, CHAHB), 
5.14 (1H, d, J = 12.3 Hz, CHAHB), 4.16 (1H, q, J = 6.9 Hz, CHCH3), 1.35 (3H, d, J = 
6.9 Hz, CHCH3), 1.17 (9H, s, (CH3)3); 13C NMR δ (151 MHz, CDCl3) 174.9 (C), 135.9 
(C), 128.6 (2 × ArCH), 128.4 (2 × ArCH), 128.3 (ArCH), 75.0 (C), 67.6 (CH), 66.4 
(CH2), 27.8 (3 × CH3), 20.6 (CH3). The spectroscopic data are in good agreement with 
the literature.203 
 
Benzyl 2-(tert-butoxy)(3,3,3-²H₃)propanoate 14 
Benzyl 2-(tert-butoxy)acetate 13 (0.500 g, 2.25 mmol) was 
dissolved in anhydrous THF (10 mL) under argon and 
cooled to -78°C before adding LiHMDS (5.63 mL, 5.63 mmol, 1 M in THF) dropwise. 
The mixture was stirred at -78°C for 1 hour before adding iodomethane-d3 (0.280 mL, 
4.50 mmol) that had previously been filtered through anhydrous potassium carbonate. 
The mixture was then allowed to warm to room temperature over 30 minutes. The 
reaction was confirmed to be completed by TLC, and hydrochloric acid (~25 mL, 0.5 
M, aq.) was added until the reaction mixture was acidic. The THF was removed in 
vacuo and ether (~20 mL) was added to the mixture. The organic layer was separated, 
and the aqueous layer was extracted with ether (3 × 10 mL). The combined organic 
layers were washed with brine (~10 mL, sat. aq.) and NaHCO3 (~10 mL, sat. aq.) 
before drying (MgSO4). The ether was removed in vacuo to give a yellow oil which 
was further purified by flash column chromatography (Hexane:EtOAc 9.5:0.5) to give 
the desired product 14 as a colourless oil (0.24 g, 1.01 mmol, 45%). Rf 
(Hexane:EtOAc 9.5:0.5) = 0.24; IR (neat cm-1) 2974 (C-H), 1753 (C=O), 1456 (ArC=C); 
1H NMR δ (600 MHz, CDCl3) 7.39-7.28 (5H, m, ArH), 5.18 (1H, d, J = 12.3 Hz, CHAHB), 
5.14 (1H, d, J = 12.3 Hz, CHAHB), 4.15 (1H, s, CHCD3), 1.18 (9H, s, (CH3)3); 13C NMR 
δ (151 MHz, CDCl3) 174.8 (C), 135.8 (C), 128.5 (2 × ArCH), 128.3 (2 × ArCH), 128.2 
(ArCH), 74.9 (C), 67.4 (CH), 66.4 (CH2), 27.7 (3 × CH3), 19.7 (CD3, sept); m/z (EI), 
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239.2 ([M+˙], 1.9%), 166.1 (100), 136.1 (26.9), 107.0 (66.0); HRMS (EI) [M+˙] found 
239.1600, C14H17D3O3 requires 239.1596. 
 
Benzyl 2-hydroxy(3,3,3-²H₃)propanoate 17 
Method A: Benzyl 2-(tert-butoxy)(3,3,3-²H₃)propanoate 14 
(0.760 g, 3.18 mmol) and triisopropylsilane (0.160 mL, 0.800 
mmol) were dissolved in anhydrous DCM (8 mL) under argon and TFA (2 mL) was 
added dropwise. The mixture was stirred at room temperature for ~48 hours until 
confirmed complete by TLC. The DCM and TFA were removed in vacuo, the residue 
dissolved in DCM (20 mL) and washed with NaHCO3 (~20 mL, sat. aq.) before drying 
(MgSO4). The DCM was removed in vacuo to give a yellow oil which was further 
purified by flash column chromatography (Hexane:EtOAc 7:3) to give the desired 
product 17 as a colourless oil (0.390 g, 2.13 mmol, 67%). 
Method B: Benzyl 2-(tert-butoxy)(3,3,3-²H₃)propanoate 14 (0.500 g, 2.10 mmol) was 
dissolved in anhydrous DCM (20 mL) and cooled to -78°C before adding titanium 
tetrachloride (2.10 mL, 2.10 mmol, 1 M in DCM) dropwise over 10 minutes. After the 
addition was complete, TLC analysis confirmed the reaction to be complete. The 
mixture was warmed to room temperature before quenching with ammonium chloride 
(~50 mL, sat. aq.). The aqueous phase was extracted with DCM (3 × 20 mL), the 
combined organic layers washed with brine (~50 mL, sat. aq.), dried (MgSO4) and the 
DCM removed in vacuo to give a yellow oil. This oil was further purified by flash 
column chromatography (Hexane:EtOAc 7:3) to give the desired product 17 as a 
colourless oil (0.360 g, 1.98 mmol, 94%). Rf (Hexane:EtOAc 7:3) = 0.44; IR (neat cm-1) 
3463 (OH), 1732 (C=O); 1H NMR δ (600 MHz, CDCl3) 7.40-7.32 (5H, m, ArH), 5.22 
(2H, s, CH2), 4.31 (1H, d, J = 4.4 Hz, CH), 2.77 (1H, d, J = 4.4 Hz, OH); 13C NMR δ 
(151 MHz, CDCl3) 175.7 (C), 135.4 (C), 128.8 (2 × ArCH), 128.7 (ArCH), 128.4 (2 × 
ArCH), 67.4 (CH2), 66.9 (CH), 19.8 (CD3, sept); m/z (EI), 183.1 ([M+˙], 6.5%), 91.1 
(100), 48.0 (56.2); HRMS (EI) [M+˙] found 183.0972, C10H9D3O3 requires 183.0969. 
 
2-Hydroxy(3,3,3-²H₃)propanoic acid 18 
Benzyl 2-hydroxy(3,3,3-²H₃)propanoate 17 (2.70 g, 14.7 mmol), Pd/C 
10% (0.54 g, 20% by weight) and THF (100 mL) were stirred under 
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hydrogen at room temperature for 3 hours before the reaction was confirmed 
complete by TLC. The reaction mixture was filtered through a celite pad before 
removing the THF under a stream of nitrogen. The residue was dissolved in water 
(~50 mL) and then washed with ether (~50 mL) before the aqueous phase was 
lyophilised to give the desired product 18 as a colourless oil (1.24 g, 13.4 mmol, 91%). 
Rf (DCM:MeOH 4:1) = 0.71; 1H NMR δ (500 MHz, D2O) 4.39 (1H, s, CH); 2H NMR δ 
(500 MHz, THF) 1.45 (3D, s, CD3); 13C NMR δ (126 MHz, D2O) 178.6 (C), 66.3 (CH), 
18.45 (CD3, sept). The spectroscopic data are in good agreement with the commercial 
product (Sigma Aldrich).  
6.2.2 H/D exchange 
Dimethyl(²H₂)-1,4-dioxane-2,5-dione 21 
Lactide 6 (0.5 g, 3.5 mmol) was dissolved in THF (5 mL) before adding 
Lindlar catalyst (2.50 g) and stirring until homogenous. The THF was 
then removed in vacuo to leave a thin film of solid coating the flask. 
The flask was evacuated and then deuterium gas was introduced via a balloon. After 
1 hour, THF (20 mL) was added to the flask and a sample was removed for crude 2H 
NMR. The catalyst was removed by centrifugation before the THF was removed in 
vacuo to give the desired product 21 as a colourless solid. 1H NMR δ (500 MHz, CDCl3) 
5.03 (1.86 H, q, J = 6.7 Hz, CH), 1.70 (6H, d, J = 6.7 Hz, CH3); 2H NMR δ (500 MHz, 
THF) 1.90 (s), 3.75 (s); 13C NMR δ (126 MHz, CDCl3) 167.5 (C), 72.5 (CH), 16.0 (CH3). 
 
(3,6-²H₂)-1,4-Dioxane-2,5-dione 22 
Glycolide 7 (0.500 g, 4.30 mmol) was dissolved in THF (5 mL) before 
adding Lindlar catalyst (2.50 g) and stirring until homogenous. The 
THF was then removed in vacuo to leave a thin film of solid coating 
the flask. The flask was evacuated and then deuterium gas was introduced via a 
balloon. After 1 hour, THF (20 mL) was added to the flask and a sample was removed 
for crude 2H NMR. The catalyst was removed by centrifugation and then the THF was 
removed in vacuo to give the desired product 22 as a colourless solid. 1H NMR δ (500 
MHz, CDCl3) 4.95 (3.72 H, s, CH2); 2H NMR δ (126 MHz, THF) 1.90 (s), 3.75 (s); 13C 







Materials and Methods 
110 
 
6.2.3 Ring closing reactions 
3,6-Dimethyl-1,4-dioxane-2,5-dione 6 
Method A: D,L-Lactic acid 4 (1.17 g, 11.0 mmol, 85% aq.) was heated 
to 230°C for 6 hours to dehydrate and form oligomers, using a Dean-
Stark trap to remove the water. Tin(II) 2-ethylhexanoate (0.68 µL, 0.1 
wt%) was added to the PLA oligomers in a Kugelrohr glass oven under high vacuum. 
The temperature was gradually increased to 230°C and the reaction was maintained 
at this temperature for 2 hours to distil off crude lactide as a colourless liquid. The 
crude lactide was further purified by flash column chromatography (Hexane:EtOAc 
7:3) to give the desired product 6 as a colourless solid (30.0 mg, 0.25 mmol, 2%). 
Method B: Ammonium hydroxide (1.53 g, 11.0 mmol, 28% aq.) was added dropwise 
to D,L-lactic acid 4 (1.17 g, 11.0 mmol, 85% aq.) and the reaction mixture was stirred 
overnight at room temperature to produce ammonium lactate. Toluene (400 mL) and 
ytterbium(III) trifluoromethanesulfonate (0.069 g, 0.10 mmol) were added to the 
ammonium lactate and the mixture was heated to reflux overnight using a Dean-Stark 
trap to remove the water. TLC analysis showed the presence of lactide in the reaction 
mixture. The reaction mixture was extracted with ethyl acetate (~100 mL) and water 
(~100 mL). The organic layer was dried (MgSO4) and the toluene and ethyl acetate 
removed in vacuo to give a colourless oil which was further purified by flash column 
chromatography (Hexane:EtOAc 7:3) to give the desired product 6 as a colourless 
solid (0.04 g, 0.29 mmol, 3%). 
Method C: D,L-Lactic acid 4 (1.17 g, 11.0 mmol, 85% aq.) and H-beta zeolite (0.500 
g), which had previously been calcined at 550°C overnight, were refluxed in toluene 
(10 mL) for 3 hours using a Dean-Stark trap to remove the water. TLC analysis 
showed the presence of lactide and PLA oligomers. The reaction mixture was filtered 
to remove the zeolite, and then acetonitrile (10 mL) and water (10 mL) were added. 
The mixture was separated and the organic layer washed with water (10 mL). The 
organic layer was dried (MgSO4) and the toluene and acetonitrile removed in vacuo 
to give the desired product 6 as a colourless solid (0.54 g, 4.8 mmol, 34%). mp 99-
101°C; IR (neat cm-1) 2995 (C-H), 1727 (C=O); Rf (Hexane:EtOAc 7:3) = 0.43; 1H 
NMR δ (500 MHz, CDCl3) 5.05 (2H, q, J = 6.7 Hz, CH), 1.70 (6H, d, J = 6.7 Hz, CH3); 
13C NMR δ (126 MHz, CDCl3) 167.5 (C), 72.5 (CH), 16.0 (CH3). The spectroscopic 
data are in good agreement with the literature.95  




6.2.4.1 Ring opening polymerisation 
Lactide 6 (0.380 g, 2.60 mmol) and glycolide 7 (0.160 g, 1.40 mmol) were added to a 
flask under nitrogen which was heated to 120°C. The monomers were allowed to fully 
melt and then dodecanol (4.50 µL, 20.0 µmol) and stannous octoate (6.50 µL, 
20.0 µmol) were added. The melt was stirred at 120°C for 20 minutes during which 
time the melt solidified and stirring stopped. The flask was then cooled to room 
temperature, quenched with MeOH (3 drops) and DCM (~1 mL) was added to dissolve 
the polymer. The polymer was then precipitated into ice-cold MeOH (~50 mL), the 
MeOH decanted off and the polymer dried in vacuo until constant weight to yield the 
desired product 8 as a white amorphous solid (0.360 g, 67%). IR (neat cm-1) 2995, 
2947 (C-H), 1747 (C=O); 1H NMR (500 MHz, CDCl3) δ 5.25-5.15 (1H, m, PLA CH), δ 
4.90-4.65 (2H, m, PGA CH2), δ 1.35-1.50 (3H, m, PLA CH3); GPC Mn = 8 733 Da, Ð 
= 1.27. The spectroscopic data are in good agreement with the literature.204  
6.2.4.2 Polycondensation polymerisation for PLGA-D 
D,L-Lactic acid 4 (0.100 g, 0.940 mmol, 85% in water), L-lactic acid-d3 18 (Sigma) 
(0.100 g, 0.910 mmol, 85% in water) and glycolic acid 5 (0.060 g, 0.790 mmol) were 
dehydrated at 150°C for 8 hours in a flask fitted with an air condenser containing 
molecular sieves, to form oligomers. Tin chloride (1.3 mg, 0.5 wt%) and para-toluene 
sulfonic acid (1.3 mg, 0.5 wt%) were then added to the oligomers followed by heating 
to 180°C for a further 8 h. The crude polymer was dissolved in DCM (2 mL) and 
precipitated into a 50:50 mixture of ice cold hexane/ether (100 mL) to yield the desired 
product 23 as a colourless solid which was dried in vacuo until constant weight (0.073 
g, 28%). 1H NMR (400 MHz, Chloroform-d) δ 5.30-5.13 (1H, m, CH), 4.93-4.56 (2H, 
m, CH2), 1.64-1.51 (3H, m, CH3). GPC Mn = 4553 g/mol, Ð = 1.84. 
 
6.3 Experimental Procedures for Chapter 3 
6.3.1 General nanoparticle methods 
6.3.1.1 Emulsification evaporation method  
A solution of PLGA 8, PLGA-D 23 or PLGA-alkyne 25 (10-20 mg) in DCM (1 mL) was 
added to the aqueous NP phase (10 mL). The two phases were emulsified using a 
probe tip sonicator for 2 minutes. The resulting emulsion was stirred at room 
temperature overnight to allow evaporation of the DCM. The NPs were collected by 
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centrifugation at 6,164 × g for 10 minutes, the supernatant removed and the NPs 
washed once with water. 
6.3.1.2 Nanoprecipitation method  
A solution of PLGA 8 (20 mg) in acetonitrile (1 mL) was added dropwise to water 
(5 mL) to spontaneously form an emulsion. The acetonitrile was removed in vacuo 
and the nanoparticles were collected by centrifugation at 9,632 × g for 10 minutes 
before washing once with water.  
6.3.1.3 Centrifugation study 
PLGA NPs (synthesised from 10 mg polymer) were synthesised using the general 
emulsification evaporation method, and before centrifugation, the NP emulsion was 
split between nine Eppendorf vials. Each of these Eppendorf vials were centrifuged 
for 10 minutes at speeds varying between 2,408 and 16,278 × g. The NPs were then 
analysed by DLS for size and polydispersity.  
6.3.1.4 Lyophilisation study 
PLGA NPs were synthesised using the general emulsification evaporation method 
(20 mg PLGA) and were then resuspended in water and split into 5 Eppendorf vials. 
One sample was not lyophilised as a control. The other 4 samples were lyophilised 
with 0, 1, 2 and 3 % (w/v) sucrose. The lyophilised powder was then resuspended in 
water (1 mL) and the NPs analysed by DLS for size and PdI.  
6.3.1.5 Nanoparticle concentration by absorption 
In triplicate, NPs (PLGA or PLGA-alkyne) were lyophilised to give a known weight of 
NPs. The lyophilised powders (~600 mg) were then resuspended in water (1 mL) and 
known concentrations (600, 300, 150 and 75 µg mL-1), produced by serial dilutions, 
were analysed by UV spectroscopy at 220 nm to produce a calibration curve.  
6.3.2 Nanoparticle targeting 
2,5-dioxopyrrolidin-1-yl 
hexadecanoate 33 
Hexadecanoic acid 31 (1.00 g, 
3.90 mmol) and triethyl amine (1.10 mL, 7.80 mmol) were dissolved in DCM (20 mL) 
before adding bis(2,5-dioxopyrrolidin-1-yl) carbonate 32 (1.20 g, 4.68 mmol) portion-
wise. The reaction was allowed to stir under argon overnight until confirmed 
completed by TLC. The reaction mixture was washed with hydrochloric acid (40 mL, 
1 M, aq.), and the aqueous layer extracted twice with DCM (2 × 20 mL). The combined 
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organic layers were dried (MgSO4) and the DCM removed in vacuo to yield the desired 
product 33 as a colourless solid (0.830 g, 2.35 mmol, 60%). Rf (CHCl3:MeOH 9.5:0.5) 
= 0.80; 1H NMR δ (500 MHz, CDCl3) 2.83 (4H, s, 2 × NHS-CH2), 2.60 (2H, t, J = 7.5 
Hz, C(O)CH2), 1.74 (2H, quin, J = 7.5 Hz, CH2), 1.40 (2H, m, CH2), 1.28 (22H, m, 11 
× CH2), 0.88 (3H, t, J = 6.9 Hz, CH3); 13C NMR (500 MHz, CDCl3) δ 169.3 (2 × C), 
168.8 (C), 32.0 (CH2), 31.0 (CH2), 29.84 (2 × CH2), 29.8 (2 × CH2), 29.77 (CH2), 29.7 
(CH2), 29.5 (2 × CH2), 29.2 (CH2), 29.0 (CH2), 25.7 (2 × CH2), 24.8 (CH2), 22.8 (CH2), 
14.26 (CH3). The spectroscopic data are in good agreement with the literature.205  
6.3.2.1 Avidin-lipid conjugates  
Avidin (from egg white) was dissolved in sodium deoxycholate solution (0.5 mL). The 
concentration found by UV spectroscopy was 1.19 mg mL-1 (8.9 nmol). A solution of 
2,5-dioxopyrrolidin-1-yl hexadecanoate 33 (5.2 µL, 89 nmol, 6 mg mL-1 in DMSO) was 
added to the avidin solution and left to react at room temperature overnight. The 
reaction was monitored by the disappearance of the avidin peak by UPLC. Once the 
reaction was complete, the protein was purified by dialysis against HEPES (1 M aq.) 
for 24 h.  
Table 6.3 UPLC method for the analysis of avidin. Waters BEH C4, 1.7 µm, 100 × 2.1 mm 
column, 60°C.  
Time (mins) %A (H2O + 0.1% TFA) %B (MeCN) 
0 80 20 
15 60 40 
17 60 40 
22 80 20 
 
Incorporation into NPs: The general emulsification evaporation method from above 
was followed but the aqueous phase was modified to be the aqueous NP phase (5 mL) 
and avidin lipid conjugates in HEPES (5 mL) synthesised from a starting concentration 
of 1 mg mL-1 avidin (5 mL).  
6.3.2.2 Carbamate conjugation of avidin to NPs  
In duplicate, avidin (5.00 mg, 75.0 nmol) and 1,1-carbonyldiimidazole (1.00 mg, 6.20 
µmol) were stirred in PBS (5 mL) at 0°C for 1 hour before the addition of either PLGA 
or PLGA-alkyne NPs (synthesised from 10.0 mg of polymer) to each of one of the 
reaction mixtures. The NPs were allowed to stir with the reaction mixture for 1 hour at 
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0°C before warming to room temperature and stirring for a further hour. The NPs were 
then isolated by centrifugation at 6,164 × g for 10 minutes. 
6.3.2.3 Adsorption of avidin to NPs  
PLGA-alkyne NPs (synthesised from 10 mg polymer) were added dropwise into 1 
mg mL-1 avidin (5 mL) in PBS and allowed to stir at room temperature overnight. The 
NPs were then isolated by centrifugation at 6,164 × g for 10 minutes. 
6.3.2.4 Click reaction of biotin azide to NPs 
Copper sulphate (0.02 mg, 0.16 µmol), sodium ascorbate (0.05 mg, 0.24 µmol) and 
tris(3-hydroxypropyltriazolylmethyl)amine (0.07 mg, 0.16 µmol) were stirred in water 
(10 mL), that had previously been degassed with nitrogen, at room temperature for 
15 minutes. Biotin-PEG3-azide conjugate (1.40 mg, 3.20 µmol) and PLGA-alkyne 
NPs (synthesised from 10 mg of PLGA alkyne, 1.6 µmol) were added to the reaction 
mixture, which was stirred at room temperature for 4 hours. The NPs were isolated 
by centrifugation at 6,164 × g for 10 minutes and were then resuspended in avidin at 
1 mg mL-1 in PBS (5 mL) and stirred overnight at room temperature.  
6.3.2.5 Biotin-HRP assay  
In triplicate, 2 × 109 particles mL-1 of the various NPs in PBS (200 µL) were added to 
1 mL Eppendorf vials before adding biotin-HRP (Thermo Fisher Scientific) at 1 mg 
mL-1 (100 µL) and incubating in the dark for 20 minutes. The Eppendorf vials were 
then centrifuged at 6,164 × g for 10 minutes to remove the biotin-HRP and washed 
once with PBS. The pellet was resuspended in PBS (200 µL) and TMB substrate 
solution (Thermo Fisher Scientific) (200 µL) was added to produce a blue colour and 
precipitate. After incubation in the dark for 20 minutes, hydrochloric acid (100 µL, 1 M 
aq.) was added to produce a yellow coloured solution that also had some blue 
precipitate. The Eppendorf vials were centrifuged once more at 6,164 × g for ten 
minutes to pellet the precipitate, and the supernatant was analysed by UV 
spectroscopy at 450 nm. 
 
6.4 Experimental Procedures for Chapter 4 
6.4.1 Isolation of microglia 
Mixed glia cultures were isolated from postnatal day 1-2 rat pups, and after 10 days, 
microglia were isolated by shaking the culture flasks relying on differential adhesion 
of oligodendrocyte precursor cells, microglia and astrocytes.206 To improve adherence 
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of microglia, all culture dishes were coated in poly-D-lysine before plating the cells by 
covering dishes in a 1 µg mL-1 aqueous solution and incubating at 37°C for one hour. 
The solution was removed and the cells were washed once with sterile water. 
Microglia were cultured in mixed glia media and were incubated at 37°C in a 
humidified atmosphere with 7.5% CO2 and media changes every 2-3 days. 
6.4.2 Viability assay 
Microglia were plated at 5 × 104 cells per well in a 96 well plate and left overnight to 
adhere to the well. PLGA, PLGA-D and PLGA-alkyne NPs, resuspended in mixed glia 
media, were then added at 1, 2 and 4 × 109 particles mL-1 and incubated for 24 hours. 
Each condition was carried out in triplicate. Viability was then assessed using the 
CellTiter-Glo ® assay (Promega). 100 µL of luciferase was added to each well, the 
plate was shaken for 2 minutes before a ten minute incubation at room temperature. 
The amount of luminescence was then assessed with a plate reader, with higher 
luminescence associated with more ATP and therefore more living cells. Three 
biological replicates of this experiment were carried out. 
6.4.3 Cell pellets 
Microglia were cultured overnight in a T75 flask before NPs (PLGA-D or PLGA-alkyne) 
were added followed by a further overnight incubation. The media was removed and 
the cells washed twice with PBS (2 × 15 mL) to remove any free NPs. Cell detachment 
was then achieved by the addition of 0.25% trypsin-EDTA solution (5 mL) and 
incubation at 37°C for 20-30 minutes. The reaction was quenched by the addition of 
mixed glia media (10 mL), before the cells were pelleted by centrifugation at 1000 
min-1 for 5 minutes. The media was aspirated and the cells re-suspended in water 
(1 mL) before lyophilisation to give a solid which was subsequently analysed by 
spontaneous Raman spectroscopy. 
6.4.4 SRS experiments on microglia 
Microglia were plated at 3 × 105 cells per well in FluoroDish Cell Culture Dishes (World 
Precision Instruments) and left overnight to adhere to the dish. NPs (alkyne or 
deuterium) were then added at concentrations between 0.5 and 2 × 109 particles mL-1, 
followed by a 24 hour incubation. The media was then removed and the cells were 
washed twice with PBS (2 × 2 mL) before fixation and imaging with SRS. 
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6.4.4.1 Time course experiments 
Microglia were plated at 3 × 105 cells per well in FluoroDish Cell Culture Dishes (World 
Precision Instruments) and left overnight to adhere to the dish. The control (t=0 h) 
cells were fixed before addition of the NPs. PLGA-alkyne NPs were then added to the 
remaining dishes at 2 × 109 particles mL-1. At 12, 24, 36 and 48 h, individual dishes 
were fixed and imaged with SRS. For each time point, three fields of view were 
imaged and the alkyne intensity per cell was quantified using ImageJ as described 
below. 
6.4.4.2 Image quantification 
• For each field of view, the protein, alkyne and off-resonance images were 
opened in ImageJ and the off-resonance was subtracted from the other two images 
using the image calculator functionality (process  image calculator).  
• A threshold (image  adjust  threshold) was then applied to the protein 
image to create a mask of just the cells. This mask was then made binary (process 
 binary  make binary). 
• To count the alkyne intensity within the cell mask only, the set measurements 
window was opened and in the redirect to box the alkyne image was selected (analyze 
 set measurements  redirect to). The measurements selected were area, mean, 
max and min grey values.  
• To then measure the values, the cell mask was selected and then the analyze 
particles functionality was used (analyze  analyze particles). The minimum size was 
set to 50.26 µm2 to exclude anything that is not a cell, and to also segment into 
individual cells. The outlines were shown to produce an image with the individual cells 
and a list of the measurements within these cells was created.  
• Three fields of view per time point were analysed and represented as a box 
plot with each dot representing one cell. The Mann-Whitney U test was used to assess 
significance. 
6.4.4.3 Encapsulation of rhodamine 
Rhodamine loaded PLGA-alkyne NPs were prepared using the standard 
emulsification-evaporation method with the addition of rhodamine (2 mg) to the 
organic phase. Microglia were plated at 3 × 105 cells per well in FluoroDish Cell 
Culture Dishes (World Precision Instruments) and left overnight to adhere to the dish. 
Rhodamine loaded PLGA-alkyne NPs were added at 2 × 109 particles mL-1 followed 
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by a 24 hour incubation. The microglia were then washed, fixed and imaged with SRS 
and TPF. 
6.4.5 Ex-vivo cortical slices 
Brains were isolated from P5 C57BL6/N mice pups in cold Hibernate-A medium 
(Thermo Fisher) on ice and cut into 300 µm cortical slices using a vibratome (Leica). 
The slices were then transferred to Millipore milli cell-CM organotypic inserts (30 mm, 
hydrophilic PTFE, 0.4 µm, Merck-Millipore) in slice media, and were maintained at 
37°C and 7.5% CO2 with media changes every two days. After 6 days in culture, 
alkyne NPs were added at 2 × 108, 2 × 109, and 2 × 1010 particles mL-1 for 24 hours. 
The slices were then washed twice with PBS (2 × 2 mL) before fixation. Slices were 
fixed with 4% formaldehyde (2 mL) for one hour at room temperature before washing 
three times with PBS (3 × 2 mL). 
6.4.5.1 Immunohistochemistry analysis 
Fixed slices in a 6 well plate were incubated with blocking solution (1 mL per well) for 
2 hours before adding the primary antibodies. Rabbit polyclonal anti-IBA1 (1/500, 
Abcam, AB178846) and mouse monoclonal anti-OLIG2 (1/500, Merck Millipore, 
MABN50) were diluted in blocking solution and 500 µL was added to each well. The 
slices were then shaken at 4°C for 1.5 days before washing three times for 1 hour 
with blocking solution (3 × 2 mL). The secondary antibodies, goat anti-rabbit 568 
(1/1000, Life Technologies, A11011), and donkey anti-mouse 488 (1/1000, Thermo 
Fisher Scientific, A21202) were diluted in blocking solution and then incubated with 
the slices (500 µL per well) with gentle agitation overnight, in the dark at 4°C. The 
slices were then washed once for 10 minutes followed by three 1 hour washes with 
PBS (4 × 2 mL) and finally imaged using TPF microscopy. 
6.4.5.2 Time course on slices 
Cortical slices were isolated as above, and three organotypic inserts were prepared 
with three slices per insert. On day five, alkyne NPs were added at 1 × 1011 particles 
mL-1 to each of the inserts by dropping the NPs suspended in 300 µL of media on top 
of the slices. At one, three and seven days after the addition of the NPs, the slices 
from one insert were fixed. The slices were then stained with anti-IBA1 for microglia 
as above. To stain nuclei in the tissue, Syto 9 Green Fluorescent Nucleic Acid Stain 
(Invitrogen, S34854) was diluted in PBS (1/1000) and 500 µL incubated with the slices 
for 2 minutes before washing three times with PBS (3 × 2 mL). The slices were then 
imaged using TPF and SRS microscopies. GFP two-photon fluorescence signals 
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were filtered using filters: FF520-Di02, FF495-Di03 and FF01-504/12. YFP two-
photon fluorescence signals were filtered using: FF520-Di02, ET570lp (chroma) and 
FF01-542/27. All other fliters were from Semrock. Nine fields of view from two slices 
were imaged for each time point.  
6.4.5.3 Image quantification 
The images from the time course studies were quantified in two ways.  
1. The average alkyne intensity within the microglia was measured for each field 
of view by creating a mask as described in Section 6.4.4.2.  
2. The percentage of microglia containing NPs was quantified for each field of 
view. In most of the images there were large clumps of microglia and NPs, 
making it hard to count individual cells, so these areas were discounted from 
the quantification. For each field of view, three squares of 140×140 pixels were 
analysed and the number of microglia, with a microglia only being counted if it 
had a clear nuclear signal, and the number of microglia containing NPs were 
counted.  
6.4.5 In vivo experiments 
Animal work was carried out in accordance with the University of Edinburgh 
regulations under Home Office rules.  
6.4.5.1 Direct injection to mouse brains 
PLGA-alkyne NPs were injected into the corpus callosum of 16 week old C57BL/6 
male mice. The mice were anaesthetized with isoflurane and a hole was drilled 
through the skull at stereotactic coordinates 1.2 mm posterior, 0.5 mm lateral, 1.4 mm 
deep to bregma. 2 µL of PLGA-alkyne NPs at 4 × 1011 particles mL-1 in PBS were then 
injected into this hole over 4 minutes using a 30 gauge needle attached to a Hamilton 
syringe, driven by a KD Scientific Nano pump, which was left in situ for 4 minutes to 
reduce backflow. At 2, or 24 hours after NP addition (2 mice per time point), mice 
were perfused with 4% formaldehyde in PBS, and the brains harvested. The brains 
were stored in 4% formaldehyde for 24 hours before being transferred to PBS. The 
brains were cut into 100 µm sections using a vibratome (Leica) prior to imaging with 
SRS microscopy.  
6.4.5.2 Intranasal delivery to mice  
Three adult C57BL/6 mice were treated with PLGA-alkyne NPs intranasally. The mice 
were anaesthetised with isoflurane and then 50 µL of PLGA-alkyne NPs at 1 × 1011 
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particles mL-1 in PBS was placed on the nostril until absorbed. The mice were held 
upside down to ensure absorption into the nostrils. 24 hours after NP addition, the 
mice were perfused with 4% formaldehyde in PBS, and the brains harvested. The 
brains were stored in 4% formaldehyde for 24 hours before being transferred to PBS. 
The brains were cut into 100 µm sections using a vibratome (Leica) prior to imaging 
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Appendix 1 Common Abbreviations 
A.U.  Arbitrary units 
ATP  Adenosine triphosphate  
BBB  Blood brain barrier 
CARS  Coherent anti-Stokes Raman scattering 
CNS  Central nervous system 
CuAAC Copper-catalysed azide-alkyne click 
Ð  Dispersity 
DCM  Dichloromethane 
DLS  Dynamic light scattering 
DMAP  4-dimethylaminopyridine 
DMEM  Dulbecco’s modified Eagle’s medium 
DMSO  Dimethyl sulfoxide 
DOX  1,3-Dioxolan-4-ones 
EDC  1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EdU  5’-Ethynyl-2’-deoxyuridine 
EGFR  Epidermal growth factor receptor 
GPC  Gel permeation chromatography 
HRP  Horseradish peroxidase 
LIF  Leukaemia inhibitory factor 
MS  Multiple sclerosis 
NG2  Neural / glial antigen 2 
NMR  Nuclear magnetic resonance 




NTA  Nanoparticle tracking analysis 
OPCs  Oligodendrocyte precursor cells 
PCA  Principal component analysis 
PdI  Polydispersity index 
PGA  Poly(glycolic acid)  
PLA  Poly(lactic acid) 
PLGA  Poly(lactic acid-co-glycolic acid) 
PPE  Poly(phenylene ethynylene) 
ROP  Ring opening polymerisation 
SEM  Scanning electron microscopy 
SERS  Surface enhanced Raman spectroscopy 
SRG  Stimulated Raman gain 
SRL  Stimulated Raman loss 
SRS  Stimulated Raman scattering 
TEM  Transmission electron microscopy 
THPTA Tris(3-hydroxypropyltriazolylmethyl)amine 
TLC  Thin layer chromatography 
TMB  Tetramethylbenzidine 
TPF  Two photon fluorescence 
UPLC  Ultra-performance liquid chromatography 


















Appendix 3 Chemical Structures of Polymers 
 
 
 
 










































